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ABSTRACT 
 
In the present investigation we compare the expression, basal activation and the ability of muscle 
stretch to activate the p70S6k pathway in the fast-twitch extensor digitorum longus (EDL) and 
slow-twitch soleus of adult (6 mo. old), aged (30 mo. old) and very aged (36 mo. old) Fischer 
344 x Brown Norway rats.  Immunoblotting demonstrated that the tissue content of mTOR, 
p70S6k, 4E-BP1 and GSK-3β decreased in the EDL and soleus in aged rats, while SHP-2 
increased in the EDL and decreased in the soleus when compared to adult rats.  Basal 
phosphorylation of 4E-BP1 increased in both the muscles; however, basal phosphorylation of 
mTOR increased in EDL while it was decreased in the very aged soleus.  Conversely, the basal 
phosphorylation of GSK-3β and SHP-2 decreased in both the muscles in aged rats.  Twenty 
percent stretch of the EDL muscle increased phosphorylation of 4E-BP1, mTOR and GSK-3ß in 
younger rats and decreased the phosphorylation of these molecules in the older rats.  The 
“mTOR”- mediated phosphorylation of p70S6k (THR 389) decreased in all the three age groups 
in the EDL,  while “ERK1/2”- mediated phosphorylation of p70S6k (THR421/SER424) increased 
in all the three age groups in the EDL, but increased only in the aged in soleus.  Conversely, 
SHP-2 phosphorylation decreased in the aged soleus.  Taken together, these data imply that 
aging affects the expression, basal phosphorylation and mechanical regulation of different 
signaling molecules in the rat EDL and soleus.  
Key Words:  EDL and Soleus; mTOR, p70S6k, GSK-3β, 4E-BP1, SHP-2, mechanotransduction, 
aging 
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CHAPTER 1 
 
INTRODUCTION 
 
 Sarcopenia is the loss of muscle mass and strength that occurs in all adults with normal 
aging [1, 2].  It is estimated that sarcopenia appears to begin in the fourth decade of life and 
accelerates during seventh decade of life [2].  The etiology of sarcopenia is unclear, but several 
factors including physical inactivity, motor-unit remodeling, decreased hormone levels, and 
decreased protein synthesis have been implicated in development of this disorder [3].  Age-
associated muscle loss and dysfunction is believed to play a major role in the pathogenesis of 
frailty and functional impairment that occurs with old age [4, 5].  The estimated direct healthcare 
cost attributable to sarcopenia in the United States in 2000 was $18.5 billion and as the number 
of older Americans is increasing, the economic costs of sarcopenia will escalate [6].  It is thought 
that the effects of sarcopenia may be delayed or largely prevented if muscle tissue could be 
induced to hypertrophy [5, 7, 8].  In adult men and women, it is well accepted that progressive 
resistance training acts to increase muscle fiber cross sectional area and mass and that these 
adaptations are diminished with increasing age [8].  Previous studies using the Fisher 344 Brown 
Norway (F344XBN) rat strain have demonstrated that aged F344XBN hybrid animals exhibit a 
large degree of age-associated muscle atrophy and a diminished ability to exhibit muscle 
hypertrophy in response to a strong hypertrophic stimulus [7, 9].    The magnitude of these age 
related deficiencies seem to be unique to this particular strain of rats and imply that this model 
may be highly suited to the mechanistic study of aged human muscle adaptation to increased 
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mechanical loading [9-11].  The cellular and molecular mechanism(s) which underlie the 
diminished ability of aged muscle to exhibit hypertrophy are not well understood.  
Increased protein synthesis, an obligatory step in cellular growth and hypertrophy, is 
thought to be regulated by changes in translational efficiency [12-14].  The factors controlling 
this stage of protein synthesis are not well understood, however, it has been well established that 
the rate of translational initiation appears to be the rate limiting step in determining the overall 
rate protein synthesis [15].  In the last few years, two factors, the 70-kDa ribosomal S6 kinase 
(p70S6k) and eukaryotic initiation factor 4E binding protein-1 (4E-BP1) have been identified as 
critical regulators in the control of initiation [14, 16-27].  Mammalian target of rapamycin 
(mTOR) is a direct target for protein kinase B (PKB)/AKT and this subsequently leads to 
increased phosphorylation of 4EBP1 and the activation of p70S6k [16, 27, 28].  4E-BP1 is a low 
molecular weight repressor of translation initiation.  When 4E-BP1 is in a dephosphorylated 
state, it is tightly bound to eukaryotic initiation factor (eIF)-4E [14].  4E-BP1 binds to and 
regulates the availability of eIF4E, which is thought to be one of the rate limiting factors for 
translational initiation [14, 29].  During stimulation, as 4E-BP1 is phosphorylated, eIF-4E breaks 
away and initiates translation, resulting in protein synthesis [14], [30].  The p70S6k is a kinase 
whose activation is dependent upon phosphorylation.  p70S6k when activated, acts to 
phosphorylate the 40S ribosomal protein, S6, at multiple sites, this phosphorylation in turn, 
causes an increase in the translation of mRNAs, and ultimately, an increase in protein synthesis 
[30].  This information is important: members of this class transcript are involved in cell cycle 
progression and the translation machinery (e.g. elongation factors, ribosomal proteins) [30].  
Illustrating this fact, is the finding that blockade of p70S6k activity results in significant inhibition 
of protein synthesis in multiple cell systems [31, 32].  Besides the positive regulators of protein 
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synthesis, the activation of glycogen synthase kinase (GSK-3β) is thought to negatively regulate 
muscle hypertrophy [33, 34] with several studies suggesting that hypertrophic stimuli inhibit the 
activity of this protein by inducing its phosphorylation [35].  The mechanism by which GSK-3β 
influences muscle growth is not certain, but this signaling protein has been implicated in the 
regulation of calcineurin substrate NFAT and the protein translation initiation factor e1F2B [33].  
SHP-2  is a protein tyrosine phosphatase prominently expressed in skeletal muscle and may 
function in a role similar to GSK-3ß, although this is controversial. Indeed SHP-2 has found to 
be positively and negatively regulate muscle growth [36].  This protein is reported to be essential 
in signaling the mitogenic effect of angiotensin II while also mediating the mitogenic effects of 
insulin-like growth factor 1 (IGF-1) in cultured cell lines [37].  How mTOR, p70S6k, 4E-BP1, 
GSK-3ß and SHP-2 may be regulated with aging in skeletal muscle is not well understood.  
Although resistance training and hypertrophy experiments have proven to be effective in 
younger individuals in building the muscle mass, their role in older individuals has been 
equivocal.  Altered ability of the older muscles to adapt to contractile stimulus could be 
associated with altered intracellular signaling regulating protein synthesis.  The understanding of 
this process, if present, may help us to better pharmacologically treat sarcopenia. 
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PURPOSE 
Our long term goal is identify the cellular and molecular mechanisms in skeletal muscle 
responsible for sarcopenia.  The purpose of this investigation was two folded.  Firstly, we 
examined how aging may alter the expression and basal phosphorylation mTOR, p70S6k, 4E-
BP1, GSK-3ß and SHP-2.  These molecules were chosen on the basis of previous data indicating 
that they are required for protein synthesis. Analysis of the data in the present study had allowed 
us to better understand the effects on aging on protein synthesis.  Based on the information from 
the previous studies, that hypertrophic stimulus does not induce hypertrophy, we chose to apply 
hypertrophic stimulus to the muscles, which is twenty percent stretch.  The second purpose was 
to determine the degree of stretch induced phosphorylation of mTOR, p70S6k, 4E-BP1, GSK-3ß 
and SHP-2 in the EDL and soleus muscles with aging.  This information had provided insight 
regarding how mechanical load regulates the activity of these molecules with aging.  The 
rationale for the proposed research was that once it is known how mTOR, p70S6k, 4E-BP1, GSK-
3ß and SHP-2 are regulated with aging and load, their activation or repression may be regulated 
pharmacologically to prevent or treat sarcopenia.  
SPECIFIC AIMS 
The objective of this study was to determine how mTOR, p70S6k, 4E-BP1, GSK-3ß and 
SHP-2 phosphorylation are regulated in aged-atrophic skeletal muscle with stretch.  We 
hypothesized that mTOR, p70S6k, 4E-BP1, GSK-3ß and SHP-2 phosphorylation with stretch will 
be attenuated with increasing age in the F344XBN hybrid rat strain.  In the present study, we 
compared the extent and time course of mTOR, p70S6k, 4E-BP1, GSK-3ß and SHP-2 
phosphorylation after twenty percent stretch in isolated fast- and slow-twitch skeletal muscles 
from different age groups of F344XBN.   
 
  Specific Aim 1: 
To determine the basal tissue content of mTOR, p70S6k, 4E-BP1, GSK-3ß and SHP-2  
in EDL and soleus with aging in F344XBN hybrid rats  To examine this possibility, 
the EDL (fast twitch) and soleus (slow twitch) muscles of rats (6-, 30-, and 36-
months) of age were harvested, homogenized and subjected to immunoblotting 
analysis.  Alterations in the expression of mTOR, p70S6k, 4E-BP1, GSK-3ß and SHP-
2 in EDL and soleus in the three age groups were evaluated by densitometry and 
statistical methods. 
Hypothesis:  
We hypothesized that age associated decrease in muscle hypertrophy were related to 
decreases in the tissue content of mTOR, p70S6k, 4E-BP1, GSK-3ß and SHP-2 in the 
EDL and soleus. 
Specific Aim 2: 
To determine the degree of stretch-induced phosphorylation of mTOR, p70S6k, 4E-
BP1, GSK-3ß and SHP-2 in EDL and soleus with aging in F344XBN hybrid rats. 
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EDL (fast twitch) and soleus (slow twitch) muscles of rats (6-, 30-, and 36-months) of 
age muscles were harvested and muscles were subjected to twenty percent stretch for 
either 5 or 15 minutes in oxygenated (95% O2, 5% CO2) Krebs-Ringer bicarbonate 
buffer maintained at 20ºC.  Phosphorylation levels were evaluated by 
immunoblotting, phosphospecific antibodies and densitometry. 
   
Hypothesis:  
We hypothesized that age associated decreases in muscle hypertrophy are related to a 
decreased ability of aged muscles to phosphorylate mTOR, p70S6k, 4E-BP1, GSK-3ß 
and SHP-2 in response to increased mechanical load.   
 
 
 
                                   
CHAPTER 2 
 
REVIEW OF THE LITERATURE 
 
INTRODUCTION 
 The following chapter presents a review of the pertinent literature concerning the present 
study.  Specifically, the following areas will be addressed: 1) age associated alterations in 
skeletal muscle and 2) the regulation of protein synthesis. 
 
Age associated alterations in skeletal muscle 
 Strength in humans has been reported to decline by the fourth [38] or only after the eighth 
decade [39].  Losses in maximal voluntary contractions (MVC) [40, 41] have ranged from 26-
38% in the quadriceps to 10-47% in the triceps surae [39, 42].  A great deal of research on aging 
has been performed on the aged rats because of the difficulties associated with aging studies in 
human e.g. ethical, cross sectional design and inability to control life time activity pattern of the 
subjects.   As with human beings, aging in animals also appears to affect muscle function.  For 
example, decreases in the maximal in vitro isometric twitch and tetanic forces of 20-35% have 
been reported for muscles of 26 month old compared with adult mice  [43-45] and rats, [46-49] 
with similar deficits for both slow and fast muscles [43, 44].  The loss of muscular strength with 
age may be related in part to a loss of muscle mass.  Young et al. (1984, 1985), [50, 51] used 
ultrasonography and found 25-35% reductions in the cross sectional area of the quadriceps 
muscle in men and women over the age of 65 years when compared to young.  The computed 
tomography scanning technique has shown similar age-related reductions in cross sectional area 
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of the psoas major and sacrospinalis muscles, [52]  the quadriceps muscle, [53] the brachial 
biceps and triceps muscles [54, 55] and the plantarflexors [54, 55] of men over the age of 65.   
 Similar to the aging human, research utilizing aged rats found similar declines in muscle 
mass [56-61].  The extent of the decline has been found to be variable and dependent upon the 
function of the muscle [3, 62-64].  Postural muscles appear to be affected more than non-postural 
muscles in rats [3, 62, 65].  Reduction in muscle mass may be due to decreases in muscle fiber 
area.  Within the limitations of cross sectional studies, type I fiber areas appear to undergo little 
change until the age of 60-70 years, [66, 67]  but changes in type II fibers are less clear.  Type II 
fiber area has been reported to decline by 40% in subjects aged 60-65 years compared to subjects 
aged 20-29 years [67, 68].  However, Aniansson and colleagues, (1980) [69] found only minor 
area reductions until the seventh decade in humans.  In rodents, several investigators have noted 
a similar, preferential reduction in type II fiber cross sectional area (CSA) and little or no decline 
in type I fiber CSA [70, 71]  but others have disputed this,  [3, 72, 73] ~30% reduction in the 
average CSA of type II fibers of the plantaris in aged 28-30 month old Long Evans rats 
compared to 9-10 month old animals.  The important conclusion drawn from the above work is 
that age associated changes in fiber cross sectional area (CSA), like muscle mass, may be 
manifested differently in various muscle fiber types and also depend on whether the muscles in 
question are weight bearing or non-weight bearing [3].  
 Skeletal muscle exhibits a great deal of plasticity, which is specific to the stimulus it 
receives [74, 75].  Hypertrophy of muscle cells in response to increased functional demand is a 
well established phenomenon.  It has been shown that resistance training in humans leads to 
muscle hypertrophy which is mainly the result of an enhanced cross-sectional area of individual 
muscle fibers [76, 77].  Similar adaptations have been observed in animals after ablation or 
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denervation of synergist muscle [77, 78].  Muscle plasticity or the ability of muscle to adapt to an 
altered contractile stimulus is decreased with aging in both humans and animals [4, 9, 11, 40, 58, 
79].  The mechanism(s) underlying age-associated changes in muscle plasticity are unknown.  
 
Summary 
 The age associated loss of muscle mass leads to a reduced force generating ability and 
eventually, a decreased functional capacity.  Due to the problems associated with performing 
invasive measures in a human population along with a lack of molecular investigations, the 
underlying mechanisms responsible for the documented alterations are unknown.  
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Protein synthesis, p70S6k, and 4E-BP1  
Contractile activity and mechanical overload in skeletal muscle stimulate protein 
synthesis, leading to enhanced fiber size and strength, and alterations in metabolic properties [80-
84].  Protein synthesis is thought to be regulated by changes in translational efficiency [15].  The 
factors controlling translational efficiency are not well understood, however it has been well 
established that the rate of translational initiation appears to be the rate limiting step in 
determining the overall rate of protein synthesis [12, 14, 15].   
Two factors, the 70-kDa ribosomal S6 kinase (p70S6k) and eukaryotic initiation factor 4E 
binding protein-1 (4E-BP1) have been identified as critical regulators in the control of initiation 
and increases in muscle cell size [14, 16, 21, 27, 85-87].  Baar and Esser 1999 demonstrated an 
increase in the rate of initiation associated with increase in the phosphorylation of p70S6k in the 
tibilais anterior and EDL muscles following high-resistance lengthening contractions.  Similarly, 
p70S6k and 4E-BP1 have been found to be activated during hypertrophy in the in vitro 
hypertrophy of C2C12 muscle cells [27].  The activation of p70S6k is thought to result in the 
selective translation of a set of growth-related mRNA containing a 5' terminal polypyrimidine 
tract (5'TOP) [32, 88-92].  This finding is important: the 5'TOP motif is found in the 5' 
untranslated region of elongation factors (eEF; e.g., eEF-1a and eEF-2) and ribosomal proteins 
(e.g., S3, S14, and S24) [32, 89, 91, 93].The immediate upstream regulator of p70S6k and 4E-BP1 
is thought to be the mammalian target of rapamycin (mTOR) [13, 94-103].  The mTOR belongs 
to the PIKK family of novel Ser/Thr kinases and functions as a key regulator of cell growth and 
cell cycle progression [104]. Research regarding the function of mTOR in skeletal muscle is not 
overly abundant.  Parkington, et al. 2004 reported increases in phosphorylation of mTOR, 
ERK1/2, and p70S6K in skeletal muscle after a single bout of in situ muscle contractile activity 
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suggesting that the activation of these factors is inter-related [94, 105].  In addition to mTOR and 
ERK 1/2, the kinases Akt/PKB and PDK1, PKCζ have also been implicated in activation of 
p70S6k in vitro [16, 27, 106, 107]. Genetic studies in Drosophila where the Akt gene has been 
activated in a constitutive fashion support the participation of Akt/PKB in the activation of 
mTOR  [108, 109] and these findings have been substantiated in cell culture studies using muscle 
cell lines [16, 27].  Whether p70S6k is regulated by a similar mechanism in vivo is unclear. 
4E-BP1 is a translation inhibitor that is phosphorylated and inactivated in response to the 
growth signals [110].  Previous studies have suggested that a major target of p42mapk / p44mapk 
(ERK1/2) activation following insulin stimulation of fat cells is 4E-BP1 [23, 111-113]. 
Phosphorylation of 4E-BP1 disrupts its interaction with protein synthesis initiation factor eIF-4E, 
liberating eIF-4E to interact with the p220 subunit of the mRNA cap binding protein complex 
[85, 114].  Similar to p70S6k, in vitro investigations using inhibitors have implicated the mTOR 
as an upstream regulator of 4E-BP1 [115].  How 4E-BP1 is regulated in differentiated skeletal 
muscle has not been fully elucidated.   
 
Negative regulators of protein synthesis 
Glycogen synthase kinase-3 (GSK-3) [116] was originally discovered as a protein kinase 
that phosphorylates and inactivates glycogen synthase [117].  Molecular cloning from a rat brain 
library revealed two GSK-3 isoforms termed α and ß which are 98% identical in their kinase 
domains [118].  GSK-3ß is thought to exert an anti-hypertrophic effect by affecting 
nuclear/cytoplasmic partitioning of the endogenous nuclear factor activating T (NF-ATs), [33, 
119, 120] c-jun,  [121-123] the eukaryotic initiation factor (eIF-2B) [124] , tau  [125]or the 
transcriptional activator ß –catenin [33, 126].  GSK-3ß is phosphorylated (inactivated) by 
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phosphorylation of serine residue 9 in response to growth factors, especially insulin and IGF-1 
[16, 27, 33, 127].  How GSK-3ß is regulated with aging in the skeletal muscle is not known. 
             SHP-2 is a widely abundant tyrosine phosphatase and very little is known and 
understood about the mechanism of action of SHP-2.  SHP2 was recently found to downregulate 
PI3K activation by dephosphorylating Gab1 [128].  Accumulating evidence implicates SHP-2 as 
a positive regulator of ERK activity downstream from receptor-tyrosine kinases [129, 130].  
SHP-2 activity is critical for the regulation of downstream events activated by growth factors 
[131, 132] however, it is unclear how SHP-2 is regulated in skeletal muscle with aging. 
 
 
Summary 
  It has been well established that the rate of translational initiation appears to be the rate limiting 
step in determining the overall rate of protein synthesis.  Previous in vitro studies have suggested 
that activation of p70S6k and 4E-BP1 might serve as a crucial regulator of muscle fiber growth 
and mTOR is thought to function as the upstream activator of p70S6k and 4E-BP1; however in 
vivo substantiation of these data has been equivocal.  Smooth muscle and cardiac muscle in vitro 
hypertrophy models have demonstrated GSK-3ß and SHP-2 as potential negative regulators of 
protein synthesis.  How GSK-3ß and SHP-2 may be regulated in vivo and with aging in skeletal 
muscle has not been investigated.   
  
CHAPTER 3 
AGING AFFECTS STRETCH-INDUCED p70S6k AND 4E-BP1 
PHOSPHORYLATION IN FAST- AND SLOW-TWITCH MUSCLE  
 S. Uddemarri and E. R. Blough 
Department of Biological Sciences, Marshall University 
             
   
ABSTRACT 
 
            In the present investigation we compare the expression, basal activation and the ability of 
muscle stretch to activate the p70S6k pathway in the fast-twitch extensor digitorum longus (EDL) 
and slow-twitch soleus of adult (6 mo. old), aged (30 mo. old) and very aged (36 mo. old) 
Fischer 344 x Brown Norway rats.  Immunoblotting demonstrated that the tissue content of 
mTOR, p70S6k, 4E-BP1 and GSK-3β decreased in the EDL and soleus in aged rats, while SHP-2 
increased in the EDL and decreased in the soleus when compared to adult rats.  Basal 
phosphorylation of 4E-BP1 increased in both the muscles, however, basal phosphorylation of 
mTOR increased in EDL while it was decreased in the very aged soleus.  Conversely, the basal 
phosphorylation of GSK-3β and SHP-2 decreased in both the muscles in aged rats.  Twenty 
percent stretch of the EDL muscle increased phosphorylation of 4E-BP1, mTOR and GSK-3ß in 
younger rats and decreased the phosphorylation of these molecules in the older rats.  The 
“mTOR”- mediated phosphorylation of p70S6k (THR 389) decreased in all the three age groups 
in the EDL,  while “ERK1/2”- mediated phosphorylation of p70S6k (THR421/SER424) increased 
in all the three age groups in the EDL, but increased only in the aged in soleus.  Conversely, 
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SHP-2 phosphorylation decreased in the aged soleus.  Taken together, these data implicate that 
aging affects the expression, basal phosphorylation and mechanical regulation of different 
signaling molecules in the rat EDL and soleus.  
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INTRODUCTION 
 Sarcopenia is the loss of muscle mass and strength that occurs in all adults with normal 
aging [1, 2].  Age-associated muscle loss and dysfunction is believed to play a major role in the 
pathogenesis of frailty and functional impairment that occurs with old age [4, 5].  It is thought 
that the effects of sarcopenia may be delayed or largely prevented if muscle tissue could be 
induced to hypertrophy [5, 7, 8].  In adult men and women it is well accepted that progressive 
resistance training acts to increase muscle fiber cross sectional area (CSA) and mass and that 
these adaptations are diminished with increasing age [8].  Previous studies by our laboratory and 
others using the Fisher 344 Brown Norway F1 hybrid (F1 hybrid) rat strain have demonstrated 
that aged F1 hybrid animals exhibit a large degree of age-associated muscle atrophy and a 
diminished ability to exhibit muscle hypertrophy in response to a strong hypertrophic stimulus 
[3, 9-11, 59, 95].  These finding suggest that similar to most human studies, muscle adaptability 
in these animals decreases with age.  The magnitude of these age related deficiencies seem to be 
unique to this particular strain of rats and imply that this model may be highly suited to the 
mechanistic study of aged human muscle adaptation to increased mechanical loading [9, 11, 59, 
133].  The cellular and molecular mechanism(s) which underlie the diminished ability of aged 
muscle to exhibit hypertrophy are not well understood.  
 Increased protein synthesis, an obligatory step in cellular growth and hypertrophy, is 
thought to be regulated by changes in translational efficiency [12-14].  The factors controlling 
this stage of protein synthesis are not well understood, however it has been well established that 
the rate of translational initiation appears to be the rate limiting step in determining the overall 
rate protein synthesis [12, 14, 15].  In the last few years, two factors, the 70-kDa ribosomal S6 
kinase (p70S6k) and eukaryotic initiation factor 4E binding protein-1 (4E-BP1) have been 
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identified as critical regulators in the control of initiation [14, 16-27].  4E-BP1 is a low molecular 
weight repressor of translation initiation.  When 4E-BP1 is in a dephosphorylated state, it is 
tightly bound to eukaryotic initiation factor (eIF)-4E [14].  4E-BP1 binds to and regulates the 
availability of eIF4E, which is thought to be one of the rate limiting factors for translational 
initiation [14, 29].  During stimulation, as 4E-BP1 is phosphorylated, eIF-4E breaks away and 
initiates translation, resulting in protein synthesis [16].  The p70S6k is a kinase whose activation is 
dependent upon phosphorylation [134].  p70S6k when activated, acts to phosphorylate the 40S 
ribosomal protein, S6, at multiple sites, this phosphorylation in turn, causes an increase in the 
translation of mRNAs, and ultimately, an increase in protein synthesis [26].  The p70S6k is 
thought to play a critical role in the translation of a class of mRNA transcripts that contain an 
oligopyrimidine tract at their transcriptional start site [26].  This fact is important because 
members of this class transcription factors are involved in cell cycle progression and the 
translation machinery (e.g. elongation factors, ribosomal proteins) [17, 30].  Illustrating this fact 
is the finding that blockade of p70S6k activity results in significant inhibition of protein synthesis 
in multiple cell systems [25, 31, 32, 135].  Recent investigations using adult animals have 
suggested that the degree of p70S6k activation with increased contractile demand is related to 
phenotypic adaptation [9, 95].  For example, Baar and Esser, (1999) demonstrated a significant 
correlation (r = 0.998) between increases in p70S6k phosphorylation and percent increase in 
muscle mass with resistance training [99].  Moreover, two elegant studies, using multiple in vitro 
[136, 137] and in vivo models [99, 138] of muscle plasticity and genetic intervention 
demonstrated that activation of p70S6k and 4E-BP1 are requisitely involved in regulating skeletal 
muscle fiber size [138].  In addition to contractile stimuli, muscle stretch has been established to 
activate p70S6k.  Torgan and others (2000) demonstrated using muscle myocytes cultured on 
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deformable membranes that increased stretch is able to activate p70S6k in a time and stretch 
dependent manner [136, 139].  In a similar fashion Hornberger et al., found that intermittent 
stretch of the mouse EDL is able to induce p70S6k phosphorylation [140] and in a follow up 
study, this same group showed that aging in mice does not alter the mechanosensitivity of the 
p70S6k signaling pathway [141].  Of interest is the finding that the EDL muscles from the CB6F1 
aged mice used in the Hornberger et al., study failed to exhibit decreases in whole muscle mass 
with aging.  This absence of whole muscle atrophy is clearly different from what we and others 
have previously observed with aging in the Fischer344 x Brown Norway hybrid rat strain and 
humans [9-11]. Such differences may be important since muscle atrophy has been suggested to 
alter the expression of signaling proteins involved in the regulation of muscle adaptation [142-
144].    
The objective of this study was to determine how p70S6k and 4E-BP1 phosphorylation is 
regulated in aged - atrophic skeletal muscle with stretch.  We hypothesized that p70S6k and 4E-
BP1 phosphorylation with stretch will be attenuated with increasing age in the Fisher 
344xBrown Norway F1 hybrid rat strain.  Because different muscle types exhibit and undergo 
altered degrees of muscle growth to loading stimuli and dissimilar amounts of age-associated 
dysfunction and atrophy with aging, it is also unclear how p70S6k protein content or activity 
might be regulated in different muscle types soleus and EDL with aging.  In the present study, 
we compared the extent and time course of p70S6k and 4E-BP1 phosphorylation after muscle 
stretch in isolated fast- and slow-twitch skeletal muscles from different age groups of F1 hybrid 
rats.  The results indicate significant muscle type specific alterations in p70S6k and 4E-BP1 
expression and stretch-induced activation with aging.  
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MATERIALS AND METHODS  
Animals  
 All procedures were performed in accordance with the Guide for the Care and Use of 
Laboratory Animals as approved by the Council of the American Physiological Society and the 
Animal Use Review Board of The Marshall University.  All procedures were conducted in strict 
accordance with Public Health Service animal welfare policy.  Adult (6 months),  aged (30 
months) and very aged (36 months) male F1 rats were obtained from the National Institute on 
Aging.   
Rats were barrier housed two per cage in an AAALAC approved vivarium.  Housing 
conditions consisted of a 12H: 12H dark-light cycle and temperature was maintained at 22 ± 2 
°C.  Animals were provided food and water ad libitum.  Rats were allowed to recover from 
shipment for at least two weeks before experimentation began, and during this time the animals 
were carefully observed and weighed weekly.  None of the older animals exhibited signs of 
failure to thrive, such as precipitous weight loss, disinterest in the environment, or unexpected 
gait alterations. 
 
Materials 
Anti- p70S6k (1:500 dilution), mTOR (1:1000 dilution), GSK-3β (1:1000 dilution), SHP-2 
(1:1000 dilution), 4E-BP1(1:1000 dilution), Thr389 phosphorylated p70S6k (1:500 dilution), 
Ser421Thr429 phosphorylated p70S6k (1:500 dilution), ser2448 phosphorylated mTOR (1:1000 dilution),  
Ser9 phosphorylated GSK-3β (1:1000 dilution), phosphorylated SHP-2 (1:1000 dilution), 
phosphorylated 4E-BP1(1:500 dilution) mouse IgG, and Rabbit IgG antibodies were purchased 
from Cell Signaling Technology (Beverly, MA).  Enhanced chemiluminescence (ECL) western 
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blotting detection reagent was from Amersham Biosciences (Piscataway, NJ).  Restore western 
blot stripping buffer was obtained from Pierce (Rockford, IL) and 3T3 cell lysates were from 
Santa Cruz Biotechnology (Santa Cruz, CA).  All other chemicals were purchased from Sigma 
(St. Louis, MO).  
 
Muscle incubation 
 Rats were anesthetized with a ketamine-xylazine (4:1) cocktail (50 mg/kg ip) and 
supplemented as necessary for reflexive response.  In a sterile environment, the dorsal surface of 
the hind limb was shaved, cleaned, and the soleus and extensor digitorum longus (EDL) muscles 
were isolated using blunt dissection.  Calipers were used to determine the in situ (Lo) resting 
muscle length of Sol and EDL at 90º ankle flexion.  Once removed from the animal, suture (2.0) 
was tied to the proximal and distal tendons and the muscles mounted in a custom designed 
incubation chamber at Lo.  Dissection and mounting procedures were performed rapidly and with 
care to prevent stretching or tearing of the muscle.  After 15 minutes of equilibration, muscles 
were subjected to 20% stretch for either 5 or 15 minutes.  All muscle incubations were 
performed in oxygenated (95% O2, 5% CO2) Krebs-Ringer bicarbonate buffer maintained at 
20ºC.  After stretch, muscles were weighed and flash frozen in liquid N2. 
 
Western blotting 
       Soleus and EDL muscles were homogenized on ice for 2 X 30 s in T-PER (2mL/100mg 
tissue weight) supplemented with 1 mM PMSF, 1 mM Na3VO4, 1 mM NaF).  After 
homogenization and centrifugation (9000 X g X 60 min. at 4ºC), the supernatant was separated 
from the pellet and stored in aliquots at -80ºC until use.  Protein concentrations of the 
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supernatant were determined in triplicate using BSA as a standard and the Bradford method 
(Pierce, Rockford, IL).  Samples were diluted to a concentration of 3mg/ml in SDS-loading 
buffer and after boiling for 5 minutes, 60 µg of total protein for each age or time point were 
separated on 7.5% SDS-PAGE gels.  Western blot transfer of protein onto nitrocellulose 
membranes was performed using standard conditions.  To verify transfer of proteins and equal 
loading of lanes the membranes were stained with Ponceau S.  For immunodetection, membranes 
were blocked in 5% Milk TBST for 1 hour at room temperature and then incubated with the 
appropriate primary antibody overnight.  After washing in TBST, the membranes were exposed 
to horseradish peroxidase-labeled IgG secondary antibody for 1 hour at room temperature.  
Protein bands were visualized with ECL (Amersham Biosciences).  Exposure time was adjusted 
to keep the integrated optical densities (IODs) within a linear and nonsaturated range, and band 
signal intensity was quantified by densitometry using a flatbed scanner (Epson Pefection 3200 
PHOTO) and Imaging software (AlphaEaseFC).  Molecular weight markers (Cell Signaling) 
were used as molecular mass standards and NIH 3T3 cell lysates were included as positive 
controls.  To allow direct comparisons between expression levels of different signaling 
molecules, immunoblots were stripped and reprobed with Restore western blot stripping buffer 
as detailed by the manufacturer (Pierce, Rockford, IL).  After verifying the absence of residual 
HRP activity on the membrane by reaction with the ECL reagent, membranes were washed and 
reprobed.   
 
Data Analysis 
Results are presented as mean ± SEM.  Multiple group comparisons were performed by one-way 
ANOVA followed by post-hoc testing where appropriate.  For all comparisons, the alpha level 
was set at P < 0.05. 
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RESULTS 
Aging effects on p70S6K pathway related protein expression and phosphorylation. 
 To investigate whether aging affected the total amount of p70S6k, mTOR, 4E-BP1, GSK-
3β and SHP-2 expression in the skeletal muscle, we performed protein gel electrophoresis and 
immunoblotting using antibodies which recognize both the unphosphorylated and 
phosphorylated forms of these molecules.  Immunoreactive bands of ~14.5kDa, ~70kDa, 
~289kDa, ~45kDa and ~72kDa corresponded to the predicted molecular mass of the 4E-BP1, 
p70S6k, mTOR, GSK-3β and SHP-2, respectively.  
 Compared to the 6-month EDL (Table 1) muscle, immunoblot analysis demonstrated 
significant decreases of ~27.3% and ~58.39% (P<0.05) and ~38.7% and ~35% (P = <0.001), 
respectively in the muscle content of p70S6k and mTOR in 30- and 36-month muscles (Figure 
1A).  In contrast, the GSK-3β and 4E-BP1 (Figure 1B) levels were not altered in the 30-month 
EDL muscles however, the expression of these molecules was significantly decreased ~44.4% 
and ~32.55% (P<0.05), respectively in the 36-month EDL muscles when compared to the 6-
month animals.  The SHP-2 levels increased ~38% in both the 30 month and 36 month in the 
EDL muscle (Figure 1B).   When compared to the 6-month soleus (Table 2) muscles, there were 
significant decreases of ~37.9% and ~68.0% (P<0.05) in p70S6k (Figure 2A), decreases of 
~23.8% and 31.5 % (P<0.05) in GSK-3 β (Figure 2B) and decreases of ~ 58% and ~60% 
(P<0.05), in the content of 4E-BP1 (Figure 2B) in the 30- and 36- month soleus samples, 
respectively.  The amount of mTOR (Figure 2A) and SHP-2(Figure 2B) levels were not altered 
in the 30-month soleus samples, however, they were significantly decreased ~47.86% (P = 
<0.001) and ~ 44.4% (P<0.001), respectively in the 36 month soleus muscles.  
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 Because p70 S6k, mTOR, 4E-BP1, GSK-3 β and SHP-2 are activated or repressed by 
phosphorylation [16, 17, 35, 80, 145-147], it was of interest to determine if the phosphorylated 
form of these proteins is altered with aging in the rat skeletal muscle.  The phosphospecific 
antibodies used for western blot analysis recognized the proteins of appropriate size p70 S6k, 4E-
BP1, mTOR, GSK-3 β and SHP-2.  Similar to our previous analysis investigating how aging 
alters the total expression of these proteins, it appears that the basal phosphorylation status of 
p70 S6k, mTOR, 4E-BP1, GSK-3 β and SHP-2 are also regulated differently with increasing age.  
In the EDL, the basal phosphorylation of mTOR (Figure 3A), 4E-BP1 (Figure 6A) and SHP-2 
(Figure 8A) did not change in the 30 month muscles when compared to samples obtained from 6 
month animals.  Conversely, in the 36-month old EDL muscles, the mTOR and 4E-BP1 levels 
were increased ~219% (P = <0.001) and ~80.33% (P = 0.002), respectively while the SHP-2 
were levels decreased ~20.71% (P = 0.041).  With respect to the EDL muscles obtained from 6-
month animals, the basal phosphorylation levels of the “ERK1/2 MAPK”- dependent 
(Thr421/Ser424) (Figure 5A) and the “mTOR”- dependent (Thr 389) (Figure 4A) form of p70 S6k 
were increased ~14% at 30-month (P = <0.001) but were not altered in the 36-month soleus.  
Conversely, the basal phosphorylation of the GSK-3 β decreased ~14% in the 30 month EDL 
muscle samples and ~36.7% in the 36 month EDL muscle samples, respectively (P = <0.001) 
(Figure 7A).  Similarly, compared to the 6 month soleus, basal phosphorylation of the mTOR 
(Figure 3B), SHP-2 (Figure 8B) and 4E-BP1 (Figure 6B) increased ~33.4% (P = <0.001) ~39% 
(P = 0.002) and ~19 % (P = <0.001), respectively in the 30 month soleus.  In the 36 month 
soleus, the mTOR and SHP-2 phosphorylation levels were decreased ~44.27% (P = <0.001) and 
~59 % (P = 0.002), respectively.  The amount of “mTOR”- mediated (Thr 389) phosphorylation 
of p70 S6k (Figure 4B) did not change with age while the “ERK1/2 MAPK”- mediated 
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(Thr421/Ser424) (Figure 5B) decreased ~23% in the 36 month (P = <0.001) soleus.  Conversely, 
the basal phosphorylation levels of the GSK-3 β (Figure 7B) decreased ~29% at the 30 month 
and ~31% in the 36 month old soleus muscles, respectively (P = <0.001). 
 
Electrophoretic determination of p70 S6k pathway and 4E-BP1 related phosphorylation in 
response to mechanical loading by twenty percent stretch.  
In parallel studies, the effect of twenty percent static stretch on the ability of the EDL and soleus 
to phosphorylate mTOR, p70 S6k, 4E-BP1, GSK-3 β and SHP-2 was determined (Table 3 and 4).  
In the six month EDL muscles, stretch increased the phosphorylation of the mTOR ~100.83% at 
15 minutes (P = <0.001) (Figure 3A).  In the 30 month EDL muscle the mTOR phosphorylation 
did not change with stretch, while in the 36 month EDL samples the mTOR phosphorylation 
with stretch decreased ~229.46% at 5 minutes and ~243.77% at 15 minutes.  In the 6 month 
EDL, the 4E-BP1 phosphorylation with stretch increased ~69% (P=<0.001) and ~98% (P=0.002) 
at 5 and 15 minutes, respectively (Figure 6A).  Conversely, in the 30 month EDL, the 4E-BP1 
phosphorylation did not change.  In the 36 month EDL muscle stretch decreased the 4E-BP1 
phosphorylation ~121% (P=0.002) at 15 minutes.  In the 6 month EDL muscles, the GSK3β 
phosphorylation was increased ~98% (P=0.002) at 5 and ~7.7% (P=0.01) at 15 minutes with 
stretch (Figure 7A).  Conversely, the stretch induced GSK3β phosphorylation was unchanged at 
any time point in the 30 month animals.  The GSK3β phosphorylation was decreased ~13% 
(P=<0.001) and ~9.1% (P=0.009) at 5 and 15 minutes, respectively in the 36 month EDL 
muscles.  In the EDL with stretch, the “mTOR”- dependent p70S6k (Thr389) phosphorylation 
(Figure 4A) was decreased ~27% (P=<0.001) and ~14.7% (P = 0.001) at 5 and 15 minutes, 
respectively in the 6 month.  Similarly, in the 30 month EDL “mTOR”- dependent p70S6k 
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(Thr389) phosphorylation decreased by ~22% and ~24.4 % at 5 and 15 minutes, respectively 
(P=<0.001).  With stretch, the “mTOR”- dependent p70S6k (Thr389) phosphorylation in the 36 
month EDL decreased ~21% (P=0.006) and ~54.9% (P=0.002) at 5 and 15 minutes, respectively.  
Stretch induced “ERK1/2 MAPK”- dependent p70S6k (Thr421/Ser424) phosphorylation (Figure 
5A) in the EDL increased in the 6 month muscles ~41.6% and ~81.63% (P = 0.002) at 5 and 15 
minutes, respectively.  Similarly, the “ERK1/2 MAPK”- dependent p70S6k (Thr421/Ser424) 
phosphorylation increased ~52.8% at 15 minutes (P = 0.003) in the 30 month old EDL muscles.  
In the 36 month EDL, the stretch induced “ERK1/2 MAPK”- dependent p70S6k (Thr421/Ser424) 
phosphorylation increased ~36.7% (P=<0.001) and ~32% (P = 0.015) at 5 and 15 minutes, 
respectively.  In contrast, the SHP-2 (Figure 8A) phosphorylation did not change with twenty 
percent stretch at any time in the 6-, 30- and 36- month age groups.  In the 6 month soleus 
subjected to twenty percent stretch, phosphorylation of the mTOR (Figure 3B) did not change at 
5 minutes, but decreased ~21%(P=0.002) at 15 minutes.  The mTOR phosphorylation with 
decreased ~40.28% and ~52.6% at 5 and 15 minutes, respectively (P=0.002) in the 30 month 
soleus.  However, in the 36 month old soleus muscles, the mTOR phosphorylation with stretch 
did not change at 5 minutes, but decreased ~17.24%(P=0.03) at 15 minutes.  Stretch induced the 
“mTOR”- dependent p70S6k (Thr389) phosphorylation (Figure 4B) in the 6 month soleus muscles 
decreased ~19.44% (P=0.014) 5 minutes.  The “mTOR”- dependent p70S6k (Thr389) 
phosphorylation was not altered with stretch at 5 and 15 minutes in the 30- or 36-month soleus 
muscles.  The “ERK1/2 MAPK”- dependent p70S6k (Thr421/Ser424) phosphorylation (Figure 
5B) did not change at 5 min and 15 minutes in the 6 month with stretch.  However, the “ERK1/2 
MAPK”- dependent p70S6k (Thr421/Ser424) phosphorylation increased with stretch ~29% 
(P=<0.001) at 15 minutes in the 30 month soleus.  With stretch the “ERK1/2 MAPK”- dependent 
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p70S6k (Thr421/Ser424) phosphorylation in the soleus increased ~28% and ~ 22% at 5 and 15 
minutes, respectively in the 36 month (P=<0.001).  In the 6 month soleus, stretch induced 
phosphorylation of the 4-EBP1 (Figure 6B) increased ~17% (P=0.002) and 47% (P=<0.001) at 5 
and 15 minutes, respectively.  Conversely, the 4E-BP1 phosphorylation  did not change with 
stretch in the 30 month, but decreased ~39% and ~60% at 5 and 15 minutes, respectively 
(P=<0.001) in the 36month soleus muscle.  In the 6 month soleus, the GSK-3 β phosphorylation 
(Figure 7B) was decreased ~25 % at 5 minutes and ~27 % at 15 minutes, respectively 
(P=<0.001).  However, with stretch, the GSK-3 β phosphorylation decreased ~7 % (P=0.001) at 
5 minutes in the 30 month with no change at 15 minutes in soleus.  Similarly, in the 36 month 
soleus, stretch induced the GSK-3 β phosphorylation decreased ~5.6% (P=0.002) at 5 minutes 
with no change at 15 minutes.  SHP-2(Figure 8B)  phosphorylation in the soleus did not change 
with twenty percent stretch at 5 and 15 minutes in 6month.  Conversely, the SHP-2  
phosphorylation in the 30 month soleus decreased ~22% (P=0.041) at 15 minutes.  On the other 
hand, SHP-2  phosphorylation with stretch in the 36 month soleus increased ~10% (P=0.024) at 
5 minutes with no change at 15 minutes.  
 
              
DISCUSSION 
The major new finding of the present study is that the muscle content and the mechanically-
induced activation of p70S6k, 4E-BP1and several of its pathway-related proteins are regulated 
differently with aging in the rat EDL and soleus.  The p70S6k and GSK-3β are thought to play a 
key role in the regulation of protein synthesis following altered loading or increased contractile 
activity [16, 137].  Indeed p70S6k has been suggested to play a critical role in the translation of 
transcripts involved in the cell cycle progression and the translational machinery [148].  In 
contrast, GSK-3β is thought to negatively regulate muscle hypertrophy [34,35] with several 
studies suggesting that hypertrophic stimuli inhibit the activity of this protein by inducing its 
phosphorylation [33, 145].  In the dephosphorylated form, 4E-BP1 is thought to partner with eIF-
4E and prevent its association with eIF-G thereby acting to inhibit protein translation [14].  SHP-
2 is a protein tyrosine phosphatase whose degree of phosphorylation has been shown to be 
positively related to its role in inhibiting the mitogenic effects of insulin-like growth factor 1 
[149,150].  On the basis of these findings and a previous study demonstrating an GSK-3β 
phosphorylation impairs its function decreased protein synthesis rate with aging, we expected 
that aging would decrease the content and degree of mTOR, p70S6k 4E-BP1 and GSK-3β basal 
phosphorylation in the soleus and EDL.  Using this same line of thought, we hypothesized that 
aging would be also be associated with an decreased degree of GSK-3β and increased SHP-2 
phosphorylation.  We demonstrate in this study, that while the tissue content of mTOR, p70S6k 
(Figure 1A) and 4E-BP1, GSK-3β and SHP-2(Figure 1B) proteins in EDL and mTOR, p70S6k 
(Figure 2A) and 4E-BP1, GSK-3β and SHP-2(Figure 2B) proteins in soleus was decreased 
significantly (p<0.05) with aging; the basal phosphorylation of the mTOR dependent forms of 
p70S6k and 4E-BP1 were significantly increased in the EDL of very aged rats (Figures 4A and 
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6A).  Conversely, the basal phosphorylation of SHP-2 and GSK-3β were decreased in very aged 
rats in EDL and soleus (Figures 7Aand B and 8 A and B).  Taken together, these alterations 
imply that aged-atrophying muscles are attempting to counteract protein breakdown by inducing 
the phosphorylation (activation) of molecules implicated in the control of protein synthesis.  
These findings are consistent with previous studies examining the phosphorylation status of 
p70S6k in aging skeletal muscle [94] and in the atrophic remodeling heart [151].  Because aging is 
characterized by significant muscle loss in this model and these data suggest that the net flux of 
protein catabolic processes exceeds that of protein anabolic processes.   Future experiments 
designed to specifically address alterations in protein breakdown will no doubt help to 
substantiate this speculation.   
 Mechanical stress has been implicated as a major factor responsible for the “functional 
health” and adaptation of striated muscle to overload.  It is well known that muscle is very 
sensitive to its loading state; unloading induces atrophy while overload causes hypertrophy [8, 
137].  The mechanism by which muscle transmits external forces into biochemical signals is not 
known.  Because aging is associated with a diminished response to muscle overload, [9-11]  we 
hypothesized that aging would diminish the ability of skeletal muscle to appropriately “sense” 
and “respond” (initiate intracellular signaling) to mechanical load (stretch).  In the present study, 
we compared the extent and time course of p70S6k and 4E-BP1 phosphorylation after muscle 
stretch in isolated fast- and slow-twitch skeletal muscles from different age groups of F344XBN 
rats.  We demonstrate that twenty percent stretch of EDL and soleus muscles in adult animals 
increases the “ERK 1/2 MAPK”- (Thr 421/Ser 424) dependent phosphorylation of p70S6k and the 
“mTOR”- (Thr 37/46) dependent phosphorylation of 4E-BP1.  Interestingly, this stretch-induced 
phosphorylation of p70S6k by ERK1/2 MAPK is conserved with aging while the stretch-induced 
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phosphorylation of 4E-BP1 by mTOR is not (Figures 5A and B and 6A and B).  This latter 
finding suggests that stretch-induced increases in mTOR activity (phosphorylation) are 
diminished with aging.  To examine this possibility we investigated the phosphorylation status of 
the mTOR Ser2448 residue (Figure 3A and B).  This residue is thought to become 
phosphorylated in response to increases in Akt/PKB activity [13, 14, 16, 27, 152, 153]  and was 
chosen since previous data has suggested that the phosphorylation status of this residue is critical 
in modulating the activity of mTOR [13, 153].  As shown in Figure 3A, we demonstrate that in 
adult animals, twenty percent stretch induces the phosphorylation of the mTOR Ser 2448 residue 
in the fast-twitch EDL but not in the slow-twitch soleus (Figure3B).  Our findings of a lack of 
mTOR Ser 2448 phosphorylation following an increased loading stimulus in the predominantly 
type I soleus muscle is consistent with a previous study by Parkington and colleagues (2003) 
who demonstrated similar findings in the soleus following a bout of high intensity concentric 
contractions.  Collectively, these data suggest that the mechanism(s) of load-induced mTOR 
activation differ between different fiber types or alternatively, that fiber type-dependent 
activation of mTOR may be unique to the acute nature of the stimulus.  Why 4E-BP1 
phosphorylation by mTOR is increased in the adult soleus with stretch without a concomitant 
increase in the activation of mTOR is unknown, but because our data is limited to selected time 
points they do not allow us to rule out any changes that may have occurred at time points that 
were not examined in this study.  It is possible that if we sampled at other time points that we 
would have found a stretch-induced changes in the phosphorylation of mTOR.  Interestingly, in 
the very aged EDL we see that increased loading induced decreases in the extent of mTOR 
phosphorylation (Figure 3A).  The physiological ramifications of this pattern of mTOR 
regulation are not known but suggest that our loading stimulus is not associated with the 
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activation of protein synthesis in this very aged muscle.  Such findings, if present, would be in 
agreement with previous demonstrating that aging increases the susceptibility of cells to 
environmental stress [128].  We demonstrate that static stretch decreases the extent of mTOR 
dependent p70S6k (Thr 389) phosphorylation in the fast-twitch EDL but not in the slow-twitch 
soleus (Figure 4 A and B).  Interestingly, this response is conserved with aging.  Why a stretch 
stimulus would act to decrease p70S6k (Thr 389) phosphorylation in one muscle type but not 
another is unknown.  Taken together, these data suggest that different fiber types respond 
differently to mechanical stimuli.  In addition, our findings that the amount of 4E-BP1 
phosphorylated by mTOR is elevated at the same time points of observation where we find no 
increases in the extent of mTOR phosphorylated p70S6k may indicate that mTOR exhibits 
different preferences in substrate phosphorylation.  Future experimentation will no doubt add to 
our understanding.    
   In conclusion, the results of this study have shown significant alterations in the skeletal 
muscle content and degree of basal phosphorylation of p70 S6k, mTOR, GSK-3β, 4E-BP1 and 
SHP-2 with aging.  In the adult EDL static stretch increases mTOR phosphorylation however 
this response is altered with aging.  The “ERK1/2 MAPK”- dependent phosphorylation of p70 S6k 
is not affected by aging in either the rat EDL or soleus while conversely, the mTOR dependent 
activation of 4E-BP1 attenuated.  This study underscores the basis for future studies investigated 
the role that mechanotransduction may play in age-related skeletal muscle signaling. 
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EDL  
Table 1 
 
Tissue concentration of mTOR, GSK-3ß, p70S6k , 4E-BP1 and SHP-2 in EDL excised 
from, aged (30 month) and very aged (36 month) in comparison to young (6month) Fischer 344X 
Brown Norway hybrid rats.  Results were obtained by the Immunoblot analysis using antibodies 
which recognized the unphosphorylated and phosphorylated forms of the proteins.  Data 
are presented as percent of the young adult value.  (NC) indicates the no change in the protein 
levels from the young adult. 
 
 
 
 
CONTENT EDL 
 30 month 36 month 
mTOR ↓(39%) ↓(35%) 
GSK-3ß NC ↓(44%) 
p70S6k ↓(27%) ↓(58%) 
4E-BP1 NC ↓(33%) 
SHP-2 ↑(38%) ↑(38%) 
 
 
 
 
 
 
Soleus  
Table 2 
Tissue concentration of mTOR, GSK-3ß, p70S6k , 4E-BP1 and SHP-2 in soleus excised 
from, aged (30 month) and very aged (36 month) in comparison to young (6month) Fischer 344X 
Brown Norway hybrid rats.  Results were obtained by the immunoblot analysis using antibodies 
which recognized the unphosphorylated and phosphorylated forms of the proteins.  Data 
are presented as percent of the young adult value.  (NC) indicates the no change in the protein 
levels from the young adult. 
 
 
CONTENT Soleus 
 30 month 36 month 
mTOR NC ↓(48%) 
GSK-3ß ↓(24%) ↓(31.5%) 
p70S6k ↓(38%) ↓(68%) 
4E-BP1 ↓(58%) ↓(60%) 
SHP-2 NC ↓(44.4%) 
Table 3: Basal phosphorylation in comparison to young (6month) and phosphorylation with 
twenty percent stretch at 5 and 15 min in comparison with control with in age group of mTOR, 
GSK-3ß, p70S6k , 4E-BP1 and SHP-2 in EDL excised from young (6month), aged (30 month) 
and very aged (36 month) and  Fischer 344X Brown Norway hybrid rats.  Results were obtained 
by the immunoblot analysis using antibodies which recognized the phosphorylated forms of the 
proteins.  Data are presented as percent of the young adult value.  (NC) indicates the no change 
in the protein levels from the young adult. 
 
 EDL 
control 5 min 15min 
p-p70(Thr389) 
 
   
          6month = ↓(27%) ↓(14.7%) 
         30 month ↑(14%) ↓(22%) ↓(24.5%) 
         36 month NC ↓(21%) ↓(54%) 
    
p-p70(Thr421Ser424) 
 
   
          6month = ↑(41.7%) ↑(81.6%) 
         30 month NC NC ↑(52%) 
         36 month NC ↑(36.7%) ↑(32%) 
    
p-GSK-3β 
 
   
          6month = NC ↑(7.7%) 
         30 month ↓(14%) ↓(10.6%) NC 
         36 month ↓(36.8%) ↓(12.9%) ↓(9%) 
    
p-SHP-2 
 
   
          6month = NC NC 
         30 month NC NC NC 
         36 month ↓(20.7%) NC NC 
    
p-4E-BP1 
 
   
          6month = ↑(69%) ↑(99%) 
         30 month NC NC NC 
         36 month ↑(80%) NC ↓(121%) 
    
p-mTOR    
          6month = NC ↑(100.8%) 
         30 month ↑(31%) NC NC 
         36 month ↑(219%) ↓(229%) ↓(243%) 
Table 4: Basal phosphorylation in comparison to young (6month) and phosphorylation with 
twenty percent stretch at 5 and 15 min in comparison with control with in age group of mTOR, 
GSK-3ß, p70S6k , 4E-BP1 and SHP-2 in soleus excised from young (6month), aged (30 month) 
and very aged (36 month) and  Fischer 344X Brown Norway hybrid rats.  Results were obtained 
by the immunoblot analysis using antibodies which recognized the phosphorylated forms of the 
proteins.  Data are presented as percent of the young adult value.  (NC) indicates the no change 
in the protein levels from the young adult. 
 
 SOLEUS 
control 5 min 15min 
p-p70 S6k (Thr389) 
 
   
          6month = NC NC 
         30 month NC NC NC 
         36 month NC NC NC 
    
p-p70 S6k (Thr421Ser424) 
 
   
          6month = NC NC 
         30 month NC NC ↑(29%) 
         36 month ↓(23%) ↑(28%) ↑(22%) 
    
p-GSK-3β 
 
   
          6month = ↓(25%) ↓(27%) 
         30 month ↓(29%) ↓(7%) NC 
         36 month ↓(31%) ↓(5%) NC 
    
p-SHP-2 
 
   
          6month = NC NC 
         30 month ↑(39%) ↓(22%) NC 
         36 month ↓(59%) ↑(10%) NC 
    
p-4E-BP1 
 
   
          6month = ↑(16.8%) ↑(47%) 
         30 month ↑(19%) NC NC 
         36 month NC ↓(39.4%) ↓(60.4%) 
    
p-mTOR    
          6month = NC ↓(21%) 
         30 month ↑(33%) ↓(40%) ↓(52%) 
         36 month ↓(44%) NC ↓(17%) 
EDL 
Figure 1 
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SOL 
Figure 2 
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P-mTOR 
Figure 3  
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P- p70s6k(Thr389) 
 
Figure 4 
 
 
 
 
 
P- p70s6k(Thr421/Ser424) 
Figure 5 
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P-4E-BP1 
Figure 6 
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P-GSK-3ß 
Figure 7 
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P-SHP-2 
Figure 8 
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FIGURE LEGENDS 
 
Figure 1. EDL tissue content of:  A) p70S6k and mTOR B) GSK-3ß, 4E-BP1 and SHP-2 in EDL  
from 6 month (young adult), 30 month (aged) and 36 month (very aged) Fischer 344/Brown 
Norway F1 hybrid rats.  Relative changes in protein levels were determined by Western blot 
analysis.  The data are presented as percent of the 6 month value (n = 4).  An asterisk, pound or 
cross indicates significant difference from the corresponding 6 month value, (p < 0.05). 
 
Figure 2. Soleus tissue content of:  A) p70S6k and mTOR B) GSK-3ß, 4E-BP1 and SHP-2 in 
soleus muscle from 6 month (young adult), 30 month (aged) and 36 month (very aged) Fischer 
344/Brown Norway F1 hybrid rats.  Relative changes in protein levels were determined by 
Western blot analysis.  The data are presented as percent of the 6 month value (n = 4).  An 
asterisk, pound or cross indicates significant difference from the corresponding 6 month value, (p 
< 0.05). 
 
Figure 3. The basal (control) and twenty percent stretch-induced phosphorylation at 5 and 15 
minutes of the mTOR in A) EDL B) soleus from 6-, 30- and 36- month old rats.  Results were 
obtained by Western blot with immunodetection for mTOR phosphorylated at Thr 2248.  
Phosphorylation status was calculated as phosphospecific optical density divided by the 6 month 
value.  An asterisk or pound indicates significant difference from the corresponding 6 month 
value or the control, respectively (p < 0.05), n = 4/group. 
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Figure 4. The basal (control) and twenty percent stretch-induced phosphorylation at 5 and 15 
minutes of the “mTOR”- dependent form of p70S6k (Thr 389) in A) EDL B) soleus from 6-, 30- 
and 36- month old rats.  Results were obtained by Western blot with immunodetection for p70S6k 
phosphorylated at Thr 389.  Phosphorylation status was calculated as phosphospecific optical 
density divided by the 6 month value. An asterisk or pound indicates significant difference from 
the corresponding 6 month value or the control, respectively (p < 0.05), n = 4/group. 
 
 
Figure 5. The basal (control) and twenty percent stretch-induced phosphorylation at 5 and 15 
minutes of the “ERK 1/2 MAPK”- dependent form of p70S6k (Thr 421/Ser 424) in A) EDL B) 
soleus from 6-, 30- and 36- month old rats.  Results were obtained by Western blot with 
immunodetection for p70S6k phosphorylated at Thr 421/Ser 424.  Phosphorylation status was 
calculated as phosphospecific optical density divided by the 6 month value.  An asterisk or 
pound indicates significant difference from the corresponding 6 month value or the control, 
respectively (p < 0.05), n = 4/group. 
 
 
Figure 6. Basal (control) and twenty percent stretch-induced phosphorylation at 5 and 15 
minutes of “mTOR”- dependent form 4E-BP1 in A) EDL B) soleus from 6, 30, and 36 month old 
rats.  Results were obtained by Western blot with immunodetection of 4E-BP1 phosphorylated at 
Thr 37/46.  Phosphorylation status was calculated as phosphospecific optical density divided by 
the 6 month value.  An asterisk or pound indicates significant difference from the corresponding 
6 month value or the control, respectively (p < 0.05), n = 4/group. 
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Figure 7. Basal (control) and twenty percent stretch-induced phosphorylation at 5 and 15 
minutes of GSK-3ß in A) EDL B) soleus from 6-, 30-, and 36- month old rats.  Results were 
obtained by Western blot with immunodetection of GSK-3ß phosphorylated at Ser 9.  
Phosphorylation status was calculated as the phosphospecific optical density divided by the 6 
month value.  An asterisk or pound indicates significant difference from the corresponding 6 
month value or the control, respectively (p < 0.05), n = 4/group. 
 
Figure 8. Basal (control) and twenty percent stretch-induced phosphorylation at 5 and 15 
minutes of SHP-2 in A) EDL B) soleus from 6-, 30-, and 36- month old rats.  Results were 
obtained by Western blot with immunodetection of SHP-2 phosphorylated on Tyr 542.  
Phosphorylation status was calculated as phosphospecific optical density divided by the 6 month 
value.  An asterisk or pound indicates significant difference from the corresponding 6 month 
value or the control, respectively (p < 0.05), n = 4/group. 
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Chapter 4 
CONCLUSIONS 
1. Aging was found to significantly decrease the soleus and EDL content of mTOR, p70S6k, GSK-3ß and 
4E-BP1.  Conversely, aging increased the content of SHP-2 in the EDL, but decreased SHP-2 content 
in the soleus. 
2. Aging significantly increased the basal phosphorylation of p- p70S6k (T389) and 4E-BP1 in the EDL .  
In the soleus, aging decreased the basal phosphorylation of p- p70S6k (421/424).  The basal 
phosphorylation of GSK-3ß and SHP-2 decreased with age in both the EDL and soleus. 
3. Twenty percent stretch of the EDL muscle increased the phosphorylation of 4E-BP1 at 5 and 15 
minutes and mTOR and GSK-3ß at 15 minutes in the younger but not in the aged or very aged EDL 
muscles.  However, SHP-2 phosphorylation with stretch did not change in all the three age groups. On 
the contrary, mTOR mediated phosphorylation of p70S6k (THR 389) decreased in all the three age 
groups and ERK1/2 mediated phosphorylation of p70S6k (THR421/SER424) increased in all the three 
age groups with twenty percent stretch.  Phosphorylation of 4E-BP1 at 5 and 15 min with twenty 
percent stretch of soleus muscle decreased with age however, mTOR mediated phosphorylation of 
p70S6k (THR 389) did not change. Conversely, ERK1/2 mediated phosphorylation of p70S6k 
(THR421/SER424) and phosphorylation of SHP-2 with stretch stimulus increased with age.  
Phosphorylation of mTOR and GSK-3ß decreases with stretch in all the three age groups. 
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FURTHER DIRECTIONS 
  
           Future directions for research based on this study should focus on the mechanisms 
associated with the differences in twenty percent stretch induced p70s6k and 4E-BP1 activation 
with aging in the F344BN EDL and soleus muscles.   
p70s6k and 4E-BP1 activation is thought to require the assimilation of many different 
upstream participants like PDK, AKT/PKB, mTOR, PKC zeta and MAPK’s [14, 16, 25, 27, 28, 
106, 153-159].  An altered activation of p70s6k and 4E-BP1 with twenty percent stretch in the 
aged may be due to differences in the amount of p70s6k and 4E-BP1 associated of PDK, 
AKT/PKB mTOR PKC zeta or MAPK’s.  Immunoprecipitation experiments using antibodies to 
any of these molecules and then probing immunoprecipatated complexes for differences in the 
amount of p70s6k and 4E-BP1 with aging would address this speculation. 
  Additionally, the present study demonstrates an increased basal phosphorylation of 
mTOR, p70s6k and 4E-BP1 with aging in the soleus and EDL muscles.   We speculate that these 
findings could be due to an increased oxidative stress in the older muscles.  Indeed, previous 
studies by Marzani et al. (2004) have demonstrated increases in the amount of reactive oxygen 
species (ROS) with aging in muscle [128].  Whether or not increased ROS might be responsible 
for age-associated increases in the basal phosphorylation of mTOR, p70s6k and 4E-BP1 with 
aging could be determined by measuring the amount of ROS present with aging and then 
employing ROS scavengers to examine whether this might decrease the phosphorylation of these 
proteins.   
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APPENDIX 
 
p70s6k EDL 
Film properties report p70s6k EDL              
  Experimenter: Sreevani Uddemarri   Muscle :  EDLSpecies: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p70s6k(Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA Secondary Antibody: Anti Rabbit  
Secondary Antibody Dilution: 1:1000 Incubation Time: 1hr @ room temp   
Medium: 5% milk in TBS-T  Exposure Time 3 min          Molecular weight: 70 kDa 
Lane 1: Rainbow Marker RPN756 3µl 
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
p70s6k in EDL Data set 
Raw IOD values (relative percentage)  
 6 month 30 month 36 month 
Raw values 36.2 36.7 27.1 
 42.6 43 14.5 
 43.2 42.8 14 
 42.2 32.8 25 
 42.6 31.1 26.2 
 40 35.4 24.6 
 58.2 27.4 14.4 
 57.8 27.8 14.4 
 57.3 28.1 14.6 
N 9 9 9 
Mean 46.67778 33.9 19.42222 
Strandard Deviation 8.581051 6.064858 6.022204 
Standard Error of the mean 3.03386 2.144251 2.129171 
% Relative expression 100 72.62557 41.60914 
SE 6.499581 4.59373 4.561423 
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Statistics 
One Way Analysis of Variance  
Normality Test: Failed (P = 0.003) 
The differences in the median values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference (P = <0.001).   
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
                         Comparison              Diff of Ranks    q P<0.05   
6 months vs 36 months 151.000 6.341 Yes   
                   6 months vs 30 months             59.000       2.478     No   
30 months vs 36 months  92.000 3.864 Yes   
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p-p70s6k EDL 
Film properties report p-p70s6k(Thr389) EDL 
Experimenter: Sreevani Uddemarri   Muscle :  EDL  Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p- p70s6k(Thr389)(Cell Signaling)Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 70 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
p-p70s6k(Thr389) in EDL Data set 
Raw IOD values (relative percentage) 
 
6 
Control 
6 
5 min 
6 
15 min 
30  
Control 
30  
5 min 
30  
15 min 
36 
Control 
36 
5 min 
36  
15 min 
Raw values 12.2 10.4 11 14.2 11.2 10.9 11 10.1 9.1 
 13 8.6 10.9 14.5 11.8 10.9 14.8 11.6 4.1 
 13.1 8.3 9.8 14.4 11.8 11.1 15.4 11.8 4.4 
 12.7 7.5 11.3 14.9 11.6 11.3 15 11.5 4.2 
 11.6 10.3 10.4 13 10.3 11.1 12.6 11 9.7 
 11.3 8.8 9.6 13.9 11.8 11.5 13.1 10.2 9.8 
N 6 6 6 6 6 6 6 6 6 
Mean 12.31667 8.983333 10.5 14.15 11.41667 11.13333 13.65 11.03333 6.883333 
Strandard Deviation 0.746771 1.147897 0.687023 0.653452 0.594699 0.233809 1.710848 0.733939 2.91439 
Standard Error of the mean 0.333966 0.513355 0.307246 0.292233 0.265957 0.104563 0.765114 0.328228 1.303355 
Relative Expression Level 100 0.729364 0.852503 1.14885 0.926928 0.903924 1.108254 0.895805 0.558863 
Standard error of the mean 0.027115 0.04168 0.024946 0.023727 0.021593 0.00849 0.06212 0.026649 0.10582 
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Statistics 
One Way Analysis of Variance 
Normality Test: Passed (P = 0.016) 
Equal Variance Test: Failed (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference (P = <0.001). 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparison   Diff of Ranks  q  P<0.05 
30 Control vs 36 15 min 287.500  6.721  Yes 
30 Control vs 6 5 min  266.000  6.218  Yes 
30 Control vs 6 15 min 197.500  4.617  Yes 
30 Control vs 6 15 min 197.500  4.617  Yes 
30 Control vs 36 5 min 146.000  3.413  No 
30 Control vs 30 15 min 145.500  3.401  Do Not Test 
30 Control vs 30 5 min 105.500  2.466  Do Not Test 
30 Control vs 6 Control 56.000   1.309  Do Not Test 
30 Control vs 36 Control 23.500   0.549  Do Not Test 
36 Control vs 36 15 min 264.000  6.171  Yes 
36 Control vs 6 5 min  242.500  5.669  Yes 
36 Control vs 6 15 min 174.000  4.067  No 
36 Control vs 6 15 min 174.000  4.067  Do Not Test 
36 Control vs 36 5 min 122.500  2.864  Do Not Test 
36 Control vs 30 15 min 122.000  2.852  Do Not Test 
36 Control vs 30 5 min 82.000   1.917  Do Not Test 
36 Control vs 6 Control 32.500   0.760  Do Not Test 
6 Control vs 36 15 min 231.500  5.412  Yes 
6 Control vs 6 5 min  210.000  4.909  Yes 
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Film properties report p- p70s6k(Thr421Ser424) EDL   
Experimenter: Sreevani Uddemarri   
Muscle : EDL   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p- p70s6k(Thr421Ser424)(Cell Signaling) Primary Antibody Dilution: 
1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 70 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
p- p70s6k(Thr421Ser424) in EDL Data set 
Raw IOD values (relative percentage) 
 
 
 
6 
Control 
6 
5 min 
6 
15 min 
30  
Control 
30  
5 min 
30  
15 min 
36 
Control 
36 
5 min 
36  
15 min 
Raw values 9.6 11.2 12.9 11.2 11.2 12.4 10 10.9 10.7 
 9.3 10.8 13.4 11.3 11.2 12.3 9.8 11.3 10.8 
 9.8 11 13.4 12 11.2 12.4 9.7 10.9 9.6 
 6.3 11.7 14.9 8 9.4 14.5 8.1 13.5 13.5 
 5.5 10.4 15.5 7.1 8.4 15.3 9.6 14.1 14.1 
 6.3 11.2 14.9 8.1 8.4 15.5 9.4 13.1 13 
N 6 6 6 6 6 6 6 6 6 
Mean 7.8 11.05 14.16667 9.616667 9.966667 13.73333 9.433333 12.3 11.95 
Strandard Deviation 1.96367 0.437035 1.061446 2.110371 1.399524 1.534492 0.68313 1.431084 1.818516 
Standard Error of the mean 0.87818 0.195448 0.474693 0.943787 0.625886 0.686246 0.305505 0.64 0.813265 
Relative Expression Level 100 141.6667 181.6239 123.2906 127.7778 176.0684 120.9402 157.6923 153.2051 
Standard error of the mean 11.2587 2.5057 6.0858 1.20998 8.0242 8.798 3.9167 8.2051 10.4265 
 
 
 
 
 
Sreevani Uddemarri   4/25/2005 
 
67
Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P = 0.011) 
Equal Variance Test: Passed (P = 0.099) 
 
Group Name    N  Missing Mean   Std Dev SEM  
 6 Control    6   0           19.104    5.335 2.178  
 6 Control    6   0           19.104    5.335 2.178  
 6 5 min    6   0           26.982     2.400 0.980  
 6 15 min    6   0           34.509    2.625 1.072  
 30 Control    6   0           25.823    3.060 1.249  
 30 5 min    6   0           27.022    2.342 0.956  
 30 15 min    6   0           38.092    8.773 3.582  
 36 Control    6   0           46.837   16.852 6.880  
 36 5 min    6   0           59.513  15.165 6.191  
 36 15 min    6   0           57.200  12.510 5.107  
 
Source of Variation    DF       SS                   MS                   F                  P   
Between Groups 9 11756.559 1306.284 15.703  <0.001  
Residual            50 4159.357 83.187    
Total                        59 15915.915     
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference (P = <0.001).  
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p70s6k Soleus 
Film properties report p70s6k Soleus 
Experimenter: Sreevani Uddemarri   
Muscle :  Soleus  Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p70s6k(Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 20 min    Molecular weight: 70 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films.  
p70s6k in Soleus Data set 
Raw IOD values (relative percentage) 
 6 month 30 month 36 month 
Raw values 48.3 34.1 17.6 
 48 34.4 17.6 
 47.9 34 18.1 
 45 38.4 16.6 
 44.7 38.6 16.7 
 42.9 39.4 17.7 
 61.9 23.8 14.3 
 60.7 23.8 15.6 
 64.4 21.5 14.1 
N 9 9 9 
Mean 51.53333 32 16.47778 
Strandard Deviation 8.344909 7.054963 1.494806 
Standard Error of the mean 3.03386 2.144251 2.129171 
% Relative expression 100 62.09573 31.97499 
SE 5.72517 4.84018 1.025538 
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Statistics 
One Way Analysis of Variance  
 
Normality Test: Passed (P > 0.200) 
Equal Variance Test: Passed (P = 0.057) 
 
Group Name           N  Missing Mean    Std Dev SEM  
                6 months             9          0             51.533      8.345 2.782  
                30 months             9          0             32.000      7.055 2.352  
                36 months             9          0             16.478      1.495 0.498  
 
       Source of Variation    DF       SS                   MS              F    P   
Between Groups 2 5554.147 2777.074 68.488  <0.001  
                 Residual      24          973.156        40.548    
                  Total       26         6527.303     
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
All Pairwise Multiple Comparison Procedures Tukey Test: 
 
Comparison                   Diff of Means p q   P P<0.050  
       6 months vs. 36 months       35.056        3    16.516   <0.001 Yes  
       6 months vs. 30 months       19.533        3      9.203   <0.001 Yes  
       30 months vs. 36 months       15.522        3      7.313    <0.001 Yes  
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p- p70s6k Soleus   
Film properties report p- p70s6k(Thr389) Soleus   
Experimenter: Sreevani Uddemarri   
Muscle :  Soleus   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p- p70s6k(Thr389)(Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 70 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl 
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
p- p70s6k(Thr389) in soleus Data set 
Raw IOD values (relative percentage)  
 
 
 
 
 
 
 
 
6 
Control 
6 
5 min 
6 
15 min 
30  
Control 
30  
5 min 
30  
15 min 
36 
Control 
36 
5 min 
36  
15 min 
Raw values 12.5 9.8 11.3 11.1 10.9 10.6 10.9 11.5 11.3 
 13 10.5 10.7 10.3 10.4 10.2 10.6 11.3 12.9 
 12.4 10.4 11.4 11.3 10.7 10 10.7 11.5 11.6 
 9.9 7.8 9.9 11 11.7 14.5 11.7 11.6 11.9 
 10.2 8.2 10.3 11.2 11.6 14.1 11.5 11.9 11 
 10.4 8.4 9.7 11.1 11.3 12.8 12 12.3 12.1 
N 6 6 6 6 6 6 6 6 6 
Mean 11.4 9.183333 10.55 11 11.1 12.03333 11.23333 11.68333 11.8 
Strandard Deviation 1.3755 1.190658 0.709225 0.357771 0.517687 2.024516 0.578504 0.360093 0.669328 
Standard Error of the mean 0.615142 0.532478 0.317175 0.16 0.231517 0.905391 0.258715 0.161038 0.299333 
Relative Expression Level 100 80.5556 92.5439 96.4912 97.3684 105.5556 98.538 102.4854 103.5088 
Standard error of the mean 5.396 4.6709 2.7822 1.4035 2.0308 7.942 2.2694 1.4126 2.6257 
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Statistics 
One Way Analysis of Variance 
Normality Test: Passed (P > 0.200) 
Equal Variance Test: Failed (P = <0.001) 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
Group            N     Missing  Median      25%       75% 
6 control 6 0 11.400       10.200   12.500 
6 5 min 6 0 9.100       8.200     10.400 
6 15 min 6 0 10.500       9.900     11.300 
30 control 6 0 11.100       11.000   11.200 
30 5 min 6 0 11.100      10.700    11.600 
30 15 min 6 0 11.700      10.200    14.100 
36 control 6 0 11.200      10.700    11.700 
36 5 min 6 0 11.550      11.500    11.900 
36 15 min 6 0 11.750      11.300    12.100 
 
H = 20.052 with 8 degrees of freedom.  (P = 0.010) 
 
The differences in the median values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference (P = 0.010) 
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Film properties report p- p70s6k(Thr421Ser424) Soleus   
Experimenter: Sreevani Uddemarri   
Muscle :  Soleus   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p- p70s6k(Thr421Ser424)(Cell Signaling)Primary Antibody Dilution: 1:1000   
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 70 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
p-p70s6k(Thr421Ser424) in Soleus Data set 
Raw IOD values (relative percentage) 
 
 
 
 
 
 
 
 
 
 
 
6 
Control 
6 
5 min 
6 
15 min 
30  
Control 
30  
5 min 
30  
15 min 
36 
Control 
36 
5 min 
36  
15 min 
Raw values 10.9 12 13.2 10 11.6 12.7 8 11.7 10 
 10.4 11.4 10.5 11.6 11.6 14.9 8.9 10.1 10.6 
 10.8 11.6 13.1 10.3 11.5 14.5 7.1 11.5 9.7 
 11.6 11.1 10.1 11.3 10.1 13.3 9.1 11.8 11.6 
 10.8 10.6 11 10.3 10.4 15.3 8.9 10.8 12 
 10.4 11.7 12.5 10.6 11.9 12.2 7.9 12.4 10.4 
N          
Mean 6 6 6 6 6 6 6 6 6 
Strandard Deviation 10.81667 11.4 11.73333 10.68333 11.18333 13.81667 8.316667 11.38333 10.71667 
Standard Error of the mean 0.440076 0.493964 1.36626 0.630608 0.741395 1.262405 0.780812 0.813429 0.904249 
Relative Expression Level 100 105.3929 108.4746 98.7673 103.3898 127.735 76.8875 105.2388 99.0755 
Standard error of the mean 1.8195 2.0423 5.6488 2.6072 3.0653 5.2194 3.2283 3.3631 3.7386 
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Statistics 
One Way Analysis of Variance  
 
Normality Test: Passed (P > 0.200) 
 
Equal Variance Test: Passed (P = 0.014) 
 
     Group Name       N    Missing     Mean              Std Dev              SEM  
        6 control         6       0         10.817            0.440             0.180  
        6 5 min         6       0         11.400                0.494             0.202  
        6 15 min         6       0         11.733            1.366             0.558  
        30 control        6       0            10.683             0.631             0.257  
        30 5 min         6       0         11.183             0.741             0.303  
        30 control        6       0          8.317             0.781             0.319  
        36 5 min         6       0          11.383             0.813             0.332  
        36 15 min        6       0            10.717             0.904             0.369  
 
Source of Variation  DF   SS     MS                  F        P   
Between Groups   8 96.623  12.078 15.676   <0.001  
Residual               45 34.672    0.770    
Total                           53 131.295     
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
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All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
              Comparison                    Diff of Means p q     P         P<0.050  
             30 15 min vs. 36 control        5.500      9   15.348     <0.001     Yes  
             30 15 min vs. 30 control        3.133      9   8.744       <0.001     Yes  
             30 15 min vs. 3615 min        3.100      9   8.651       <0.001     Yes  
             30 15 min vs. 6 control        3.000      9   8.372       <0.001     Yes  
             30 15 min vs. 30 5 min        2.633      9   7.349      <0.001     Yes  
             30 15 min vs. 36 5 min        2.433      9   6.790      <0.001     Yes  
             30 15 min vs. 6 5 min        2.417      9   6.744      <0.001     Yes  
             30 15 min vs. 6 15 min        2.083      9   5.814        0.005     Yes  
             6 15 min vs. 36 control        3.417      9   9.534      <0.001     Yes  
             6 15 min vs. 30 control        1.050      9   2.930        0.504      No  
             6 15 min vs. 36 15 min        1.017             9   2.837        0.547 Do Not Test  
             6 15 min vs. 6 control        0.917      9   2.558        0.676 Do Not Test 
             6 15 min vs. 30 5 min        0.550      9   1.535        0.974 Do Not Test  
             6 15 min vs. 36 5 min        0.350      9   0.977        0.999 Do Not Test  
             6 15 min vs. 6 5 min                    0.333      9   0.930        0.999 Do Not Test  
             6 5 min vs. 36 control        3.083      9   8.604       <0.001      Yes  
             6 5 min vs. 30 control        0.717      9   2.000        0.886 Do Not Test  
             6 5 min vs. 36 15 min        0.683      9   1.907        0.911 Do Not Test  
             6 5 min vs. 6 control                    0.583      9   1.628        0.963 Do Not Test  
             6 5 min vs. 30 5 min                    0.217      9   0.605        1.000 Do Not Test  
             6 5 min vs. 36 5 min                    0.0167      9       0.0465      1.000 Do Not Test  
             36 5 min vs. 36 control        3.067      9   8.558       <0.001      Yes  
             36 5 min vs. 30 control        0.700      9   1.953         0.899 Do Not Test   
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4E-BP1 EDL 
Film properties report 4E-BP1 EDL 
Experimenter: Sreevani Uddemarri   
Muscle :  EDL   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 10% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: 4E-BP1(Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 14.5kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
4E-BP1 in EDL Data set 
Raw IOD values (relative percentage) 
 
 
 
 
 6 month 30 month 36 month 
Raw values 11.6 14 9.7 
 11.2 14 10.1 
 11.6 13.8 10.2 
 18.9 12.5 9.6 
 18.8 12.2 9.1 
 18.9 12.7 9.6 
N 6 6 6 
Mean 14.42 13.3 9.74 
Strandard Deviation 6.910982 5.486134 3.995706 
Standard Error of the mean 3.090685 2.453474 1.786934 
% Relative expression 100 92.233 67.5451 
SE 21.4333 17.0144 12.3921 
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Statistics 
One Way Analysis of Variance  
 
Normality Test: Passed (P = 0.049) 
Equal Variance Test: Failed (P = <0.001) 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
 
Group          N    Missing  Median    25%      75%    
                   6 control        6               0          15.200       11.600         18.900  
                   30 control      6               0          13.250       12.500         14.000  
                   36 control      6               0          9.650       9.600         10.100  
 
H = 11.416 with 2 degrees of freedom.  (P = 0.003) 
 
The differences in the median values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = 0.003) 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
                            Comparison                         Diff of Ranks     q P<0.05   
                            6 control   vs 36 control         54.000 4.129   Yes   
                            6 control   vs 30 control              0.000       0.000    No   
                            30 control vs 36 control         54.00       4.129   Yes   
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p-4E-BP1 EDL 
Film properties report p-4E-BP1 EDL 
Experimenter: Sreevani Uddemarri   
Muscle :  EDL   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 10% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p-4E-BP1 (Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 14.5 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                    
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
p-4E-BP1 in EDL Data set 
Raw IOD values (relative percentage) 
 
 
6 
Control 
6 
5 min 
6 
15 min 
30  
Control 
30  
5 min 
30  
15 min 
36 
Control 
36 
5 min 
36  
15 min 
Raw values 6.5 15.2 16.1 9 8.5 13.2 18.3 9 4.2 
 6.3 14.9 15.2 8.9 8.6 13.5 18.1 9.7 4.9 
 6.3 15.3 15.6 9 9 13.5 18 9 4.5 
 9.8 12.1 16.3 11.2 13.3 9.8 10.9 11.8 4.7 
 9.5 11.8 15.9 10.7 13 9.2 10.6 13.1 6.2 
 9.9 12.3 16.9 11.5 15 9.5 11.2 9.8 4 
N 6 6 6 6 6 6 6 6 6 
Mean 8.05 13.6 16 10.05 11.23333 11.45 14.51667 10.4 4.75 
Strandard Deviation 1.850135 1.692336 0.586515 1.214496 2.862633 2.147324 3.967577 1.674515 0.781665 
Standard Error of the mean 0.827406 0.756836 0.262298 0.543139 1.280208 0.960312 1.774354 0.748866 0.349571 
Relative Expression Level 100 168.9441 198.7578 124.8447 139.5445 142.236 180.3313 129.1925 59.0062 
Standard error of the mean 10.2783 9.4017 3.2584 6.7471 15.9032 11.9293 22.0417 9.3027 4.3425 
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Statistics 
One Way Analysis of Variance 
 
Normality Test: Passed (P > 0.200) 
Equal Variance Test: Failed (P = <0.001) 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
 
Group         N      Missing  Median    25%      75% 
                          6 control      6 0    8.000   6.300              9.800 
                          6 5 min        6 0    13.600   12.100            15.200 
                          6 15 min      6 0    16.000   15.600            16.300 
                          30 control    6 0    9.850   9.000              11.200 
                          30 5 min      6 0    11.000   8.600              13.300 
                          30 15min     6 0    11.500   9.500              13.500 
                          36 control    6 0    14.600   10.900  18.100 
                          36 5 min      6 0    9.750   9.000              11.800 
                          36 15 min    6 0    4.600   4.200              4.900 
 
H = 36.715 with 8 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001) 
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4E-BP1 Soleus 
Film properties report 4E-BP1 Soleus 
Experimenter: Sreevani Uddemarri   
Muscle :  Soleus   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 10% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: 4E-BP1(Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 14.5 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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 Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
4E-BP1 in Soleus Data set 
Raw IOD values (relative percentage) 
 6 month 30 month 36 month 
Raw values 21.7 12.6 8.8 
 21.8 12.6 8.7 
 21.6 12.8 8.6 
 30 8.3 11.3 
 27.7 8.5 11.5 
 27.4 8.4 11.2 
N 6 6 6 
Mean 25.03333 10.53333 10.01667 
Strandard Deviation 3.761205 2.338946 1.446951 
Standard Error of the mean 1.682062 1.046008 0.647096 
% Relative expression 100 42.0772 40.0133 
SE 6.7193 4.1785 2.5849 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P = 0.154) 
 
Equal Variance Test: Failed (P = <0.001) 
 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
 
   Group           N       Missing      Median      25%      75%    
                6control             6            0       24.600     21.700 27.700  
                30control             6            0       10.550     8.400 12.600  
                36control             6            0       10.000     8.700 11.300  
 
H = 11.380 with 2 degrees of freedom.  (P = 0.003) 
 
The differences in the median values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = 0.003) 
 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparison                     Diff of Ranks   q P<0.05 
            6 control vs 36 control     54.000  4.129     Yes   
            6 control vs 30 control     54.000  4.12       Yes   
            30 control vs 36 control     0.000  0.000      No   
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p-4E-BP1 Soleus 
Film properties report p-4E-BP1 Soleus 
Experimenter: Sreevani Uddemarri   
Muscle :  Soleus   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p-4E-BP1 (Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 14.5 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
p-4E-BP1 in Soleus Data set 
Raw IOD values (relative percentage) 
 
6 
Control 
6 
5 min 
6 
15 min 
30  
Control 
30  
5 min 
30  
15 min 
36 
Control 
36 
5 min 
36  
15 min 
Raw values 11.4 12.5 16 14.7 14.1 10.3 9.5 6.5 5.1 
 11.9 12.4 16.1 14 14.4 10.3 10 6.7 4.3 
 11.7 12.2 16.1 14.1 13.7 10.4 10.5 7.3 4.1 
 11 13.8 17.3 12.7 10.7 13.3 11.5 6.1 3.7 
 11 14.4 17 12.7 10.5 12.7 11.9 5.9 3.7 
 10.7 13.8 17.3 12.7 10.4 13 12.1 6.3 3.7 
N 6 6 6 6 6 6 6 6 6 
Mean 11.28333 13.18333 16.63333 13.48333 12.3 11.66667 10.91667 6.466667 4.1 
Strandard Deviation 0.462241 0.926103 0.631401 0.89088 1.950385 1.473318 1.070358 0.496655 0.551362 
Standard Error of the mean 0.20672 0.414166 0.282371 0.398414 0.872238 0.658888 0.478679 0.222111 0.246577 
Relative Expression Level 100 116.839 147.4151 119.4978 109.0103 103.3973 96.7504 57.3117 36.3368 
Standard error of the mean 1.8321 3.6706 2.5025 3.531 7.7303 5.8395 4.2424 1.9685 2.1853 
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Statistics 
One Way Analysis of Variance 
Normality Test: Passed (P > 0.200) 
Equal Variance Test: Failed (P = <0.001) 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
Group     N    Missing  Median    25%      75% 
                        6 control    6       0               11.200   11.000 11.700 
                        6 5 min      6       0               13.150   12.400 13.800 
                        6 15 min    6       0               16.550   16.100 17.300 
                        30 control  6       0               13.350   12.700 14.100  
                        30 5 min    6       0               12.200   10.500 14.100 
                        30 15 min  6       0               11.550   10.300 13.000 
                        36 control  6       0               11.000   10.000 11.900 
                        36 5 min    6       0               6.400               6.100              6.700 
                        36 15 min  6       0               3.900               3.700    4.300 
 
H = 43.647 with 8 degrees of freedom.  (P = <0.001) 
 
The differences in the median values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001) 
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All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparison         Diff of Ranks    q   P<0.05 
615 min vs 3615 min   288.000 7.474     Yes 
615 min vs 365 min   252.000  6.539    Yes 
615 min vs 36 control   178.000  4.619    Yes 
                                     615 min vs 6 control     160.000   4.152      No 
                                     615 min vs 3015 min    148.000          3.841     Do Not Test 
                                     615 min vs 305 min      119.500   3.101     Do Not Test 
                                     615 min vs 65 min        83.500            2.167     Do Not Test 
                                     615 min vs 30 control   67.000   1.739     Do Not Test 
                                     30 control vs 36 15 min221.000   5.735      Yes 
                                     30control vs 365 min    185.000   4.801      Yes 
                                     30control vs 36control  111.000   2.880       No  
                                     30control vs 6 control    93.000   2.413     Do Not Test 
            30control vs 3015 min  81.000  2.102     Do Not Test 
                                     30control vs 305 min    52.500   1.362     Do Not Test 
                                     30 control  vs 65 min    16.500   0.428     Do Not Test 
                                     65 min vs 3615 min    204.500   5.307       Yes 
                                     65 min vs 365 min    168.500   4.373        No 
                                     65 min vs 36 control     94.500   2.452      Do Not Test 
                                     65 min vs 6 control       76.500   1.985      Do Not Test 
                                     65 min vs 3015 min      64.500            1.674      Do Not Test  
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mTOR EDL 
Film properties report mTOR EDL 
Experimenter: Sreevani Uddemarri   
Muscle :  EDL   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: mTOR (Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 280 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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 Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
mTOR in EDL Data set 
Raw IOD values (relative percentage)  
 6 month 30 month 36 month 
Raw values 47.3 25.1 27.6 
 53.7 22 24.2 
 40.3 31.1 28.6 
 41.2 30.1 28.7 
 42.1 26.7 31.2 
 40.4 27.5 32 
N 6 6 6 
Mean 44.16667 27.08333 28.71667 
Strandard Deviation 5.346276 3.32651 2.778789 
Standard Error of the mean 2.390927 1.48766 1.242712 
% Relative expression 100 61.3208 65.0189 
SE 5.4134 3.3683 2.8137 
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Statistics 
One Way Analysis of Variance  
Normality Test: Passed (P > 0.200) 
Equal Variance Test: Passed (P = 0.658) 
 
           Group Name  N  Missing Mean  Std Dev SEM  
                             6 control    6      0             44.167    5.346   2.183  
                             30 control   6      0             27.083    3.327   1.358  
                             36 control   6      0             28.717    2.779   1.134  
 
  Source of Variation  DF    SS     MS        F           P    
                          Between Groups    2     1066.421  533.211  33.769  <0.001  
       Residual                       15   236.850    15.790    
                           Total                            17   1303.271     
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparison               Diff of Means p    q P P<0.050 
           6 control vs. 30 control 17.083             3 10.531 <0.001    Yes  
           6 control vs. 36 control 15.450             3 9.524 <0.001    Yes  
           36 control vs. 30 control 1.633             3 1.007   0.760     No  
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p-mTOR EDL 
Film properties report p-mTOR EDL 
Experimenter: Sreevani Uddemarri  Muscle :  EDL Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p-mTOR (Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 42, 44 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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 Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
p-mTOR in EDL Data set 
Raw IOD values (relative percentage) 
 
6 
Control 
6 
5 min 
6 
15 min 
30  
Control 
30  
5 min 
30  
15 min 
36 
Control 
36 
5 min 
36  
15 min 
Raw values 9 8.4 19.2 10.1 8.8 8 24.9 5.8 5.8 
 9.5 7.1 20.3 10.8 8.9 7.2 26.8 4.8 4.6 
 10.1 9 15.4 9.5 13.1 12.1 19.1 7.6 4.1 
 10.6 11.8 15.4 7.8 12.2 12.7 19.1 6.6 3.6 
 4.7 5.9 13.1 12.3 8.5 5.5 32.2 8.9 8.8 
 4.3 5.2 13.4 12.6 8.2 5.6 31.7 9.5 9.4 
N 6 6 6 6 6 6 6 6 6 
Mean 8.033333 7.9 16.13333 10.51667 9.95 8.516667 25.63333 7.2 6.05 
Strandard Deviation 2.792609 2.391652 2.983734 1.799352 2.124853 3.160643 5.782618 1.812181 2.480121 
Standard Error of the mean 1.248893 1.069579 1.334366 0.804695 0.950263 1.413483 2.586065 0.810432 1.109144 
Relative Expression Level 100 98.34025 200.8299 130.9129 123.8589 106.0166 319.0871 89.62656 75.3112 
Standard error of the mean 15.54638 13.31427 16.61037 10.01694 11.829 17.59522 32.19168 10.08836 13.80677 
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Statistics 
One way analysis of variance  
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
       Power of performed test with alpha = 0.050: 1.000 
       All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison              Diff of Means       p      q        P     P<0.050 
                     36 control vs. 3615 min    19.583    9 15.792   <0.001   Yes  
                     36 control vs. 36 5 min     18.433    9 14.865  <0.001    Yes  
                     36 control vs. 6 5 min    17.733    9 14.300  <0.001    Yes  
                     36 control vs. 6 control     17.600    9  14.193  <0.001    Yes  
                     36 control vs. 30 15 min   17.117    9 13.803  <0.001    Yes  
                     36 control vs. 30 5 min    15.683    9 12.647  <0.001    Yes  
                     36 control vs. 30 control   15.117    9 12.190  <0.001    Yes  
                     36 control vs. 6 15 min    9.500    9 7.661  <0.001    Yes  
                     6 15 min vs. 3615 min    10.083    9 8.131  <0.001    Yes  
                     6 15 min vs. 36 5 min     8.933    9 7.204  <0.001    Yes  
                     6 15 min vs. 6 5 min    8.233    9 6.640  <0.001    Yes  
                     6 15 min vs. 6 control     8.100    9 6.532    0.001    Yes  
                     6 15 min vs. 3015 min    7.617    9 6.142    0.002    Yes  
                     6 15 min vs. 30 5 min    6.183    9 4.986    0.025    Yes  
                     6 15 min vs. 30 control    5.617    9 4.529    0.057     No  
                     30 control vs. 3615 min    4.467    9 3.602    0.238     No 
                     30 control vs. 365 min     3.317    9 2.675    0.623     Do Not Test  
                     30 control vs. 6 5 min    2.617    9 2.110    0.853     Do Not Test  
                     30 control vs. 6 control     2.483    9 2.003    0.886     Do Not Test  
               30 control vs. 30 15 min   2.000          9       1.613      0.964     Do Not Test  
               30 control vs. 30 5 min     0.567               9       0.457      1.000     Do Not Test  
               30 5 min vs. 36 15 min     3.900          9       3.145      0.409     Do Not Test  
                     30 5 min vs. 36 5 min     2.750    9 2.218    0.816     Do Not Test 
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mTOR Soleus 
Film properties report mTOR Soleus 
Experimenter: Sreevani Uddemarri   
Muscle :  Soleus   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: mTOR (Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 280 kDa 
Lane 1: Rainbow Marker RPN756 3µl 
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
mTOR in Soleus Data set 
Raw IOD values (relative percentage) 
 6 month 30 month 36 month 
Raw values 40.4 39.1 20.5 
 39.9 39.9 20.3 
 40.2 37.4 22.4 
 40.1 37.8 22.1 
 40.4 40.8 18.8 
 39.1 39.7 21.1 
N 6 6 6 
Mean 40.01667 39.11667 20.86667 
Strandard Deviation 0.487511 1.301409 1.315548 
Standard Error of the mean 0.218021 0.582008 0.588331 
% Relative expression 100 97.7509 52.1449 
SE 0.5448 1.4544 1.4702 
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Statistics 
One Way Analysis of Variance  
Normality Test: Passed (P > 0.200) 
Equal Variance Test: Passed (P = 0.130) 
 
Group Name       N     Missing Mean   Std Dev SEM 
                             6 control            6          0              40.017    0.488 0.199  
                             30 control        6          0              39.117    1.301 0.531  
                             36 control        6          0              20.867    1.316 0.537  
 
                        Source of Variation       DF      SS             MS            F            P  
                              Between Groups          2     1401.190 700.595 573.945 <0.001  
                              Residual                      15   18.310 1.221    
                              Total                      17   1419.500     
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
      Power of performed test with alpha = 0.050: 1.000 
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p-mTOR Soleus 
Film properties report p-mTOR Soleus 
Experimenter: Sreevani Uddemarri   
Muscle :  Soleus   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p-mTOR (Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 42, 44 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
p-mTOR in SoleusData set  
Raw IOD values (relative percentage) 
 
6 
Control 
6 
5 min 
6 
15 min 
30  
Control 
30  
5 min 
30  
15 min 
36 
Control 
36 
5 min 
36  
15 min 
Raw values 12.4 10.6 10.6 18.4 15.7 13.4 9.4 5.8 3.6 
 13.1 10.2 10.5 17.6 14.9 13.7 9.3 6.3 4.4 
 15.1 10.3 11.1 19.2 14.6 13.1 8.2 5 3.3 
 14.8 14.8 11 18.5 10.6 9.2 6.5 7.8 6.8 
 14.3 16.6 10.9 19.1 10.5 8.8 6.1 7.3 6.3 
 13.2 16.4 11.4 17.8 10.9 8.8 6.7 7.2 7.5 
N 6 6 6 6 6 6 6 6 6 
Mean 13.81667 13.15 10.91667 18.43333 12.86667 11.16667 7.7 6.566667 5.316667 
Strandard Deviation 1.072225 3.114964 0.33116 0.653197 2.440219 2.458184 1.462874 1.055778 1.776982 
Standard Error of the mean 0.479514 1.393054 0.148099 0.292119 1.091299 1.099333 0.654217 0.472158 0.794691 
Relative Expression Level 100 95.17491 79.01086 133.4138 93.12425 80.82027 55.72979 47.52714 38.4801 
Standard error of the mean 3.470545 10.08242 1.071887 2.114249 7.898424 7.956573 4.734985 3.417309 5.751682 
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Statistics 
 
One Way Analysis of Variance 
 
Normality Test: Passed (P > 0.200) 
Equal Variance Test: Passed (P = 0.649) 
 
Group Name  N  Missing Mean   Std Dev SEM  
                         6 control  6    0            14.867   1.763             0.720  
                         6 5 min 6    0            12.233   3.058             1.248  
                         6 15 min 6    0            10.533   0.944             0.385  
                         30 control 6    0            16.117   2.766             1.129  
                         30 5 min 6    0            11.133   2.606             1.064  
                         30 15 min 6    0            10.183   2.375             0.970   
                         36 control 6    0            8.683   1.659             0.677  
                         36 5 min 6    0            8.300   2.770             1.131  
                         3615 min 6    0            7.983   3.451             1.409  
 
             Source of Variation   DF     SS        MS    F    P   
                    Between Groups         8       391.161 48.895    7.891   <0.001  
              Residual               45      278.827      6.196    
                                Total                     53      669.988     
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
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All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
 
                     Comparison Diff of Means   p q P P<0.050  
30 control vs. 3615 min 8.133 9 8.004 <0.001 Yes  
30 control vs. 365 min 7.817 9 7.692 <0.001 Yes  
30 control vs. 36 control 7.433 9 7.315 <0.001 Yes  
30 control vs. 3015 min 5.933 9 5.839 0.005 Yes  
30 control vs. 615 min 5.583 9 5.494 0.009 Yes  
30 control vs. 305 min 4.983 9 4.904 0.029 Yes  
                   30 control vs. 65 min        3.883   9         3.821   0.176  No 
            30 control vs. 6 control  1.250   9 1.230 0.994 Do Not Test  
6 control  vs. 3615 min 6.883 9 6.774 <0.001 Yes  
                   6 control  vs. 365 min        6.567    9         6.462   0.001  Yes  
                   6 control  vs. 36 control        6.183   9         6.085   0.003  Yes  
6 control  vs. 3015 min 4.683 9 4.609  0.050 Yes  
                   6 control  vs. 615 min        4.333   9        4.264    0.089   No  
                  6 control  vs. 305 min       3.733   9       3.674    0.216  Do Not Test  
            6 control  vs. 65 min             2.633   9 2.591 0.661 Do Not Test  
                   65 min vs. 3615 min        4.250   9        4.182    0.102   No  
                 65 min vs. 365 min       3.933   9       3.871   0.164   Do Not Test  
                   65 min vs. 36 control        3.550   9        3.493    0.274   Do Not Test  
                   65 min vs. 3015 min        2.050   9        2.017    0.882   Do Not Test  
                   65 min vs. 615 min       1.700    9       1.673     0.956   Do Not Test  
                   65 min vs. 305 min       1.100    9       1.082     0.997   Do Not Test  
                  305 min vs. 3615 min       3.150    9       3.100     0.428   Do Not Test  
                  305 min vs. 365 min       2.833    9       2.788     0.570   Do Not Test  
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GSK-3ß EDL 
Film properties report GSK-3ß EDL 
Experimenter: Sreevani Uddemarri   
Muscle :  EDL   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 10% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: GSK-3ß(Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 45 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
GSK-3ß in EDL Data set 
Raw IOD values (relative percentage)  
 6 month 30 month 36 month 
Raw values 13.8 16.1 7.3 
 13.4 13.5 7.4 
 15.9 12.6 8.4 
 12.3 15.8 5.1 
 10.8 17.6 8.3 
 15.9 13.9 8 
 14.6 13.7 8.3 
 12.6 13.8 8 
N 8 8 8 
Mean 13.6625 14.625 7.6 
Strandard Deviation 1.779195 1.683322 1.090216 
Standard Error of the mean 0.672473 0.636236 0.412063 
% Relative expression 100 107.0448 55.6267 
SE 4.922 4.6568 3.016 
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Statistics 
 
One Way Analysis of Variance  
 
Normality Test: Passed (P > 0.200) 
Equal Variance Test: Passed (P = 0.390) 
 
   Group Name      N    Missing     Mean    Std Dev  SEM  
                                6 months         8         0         13.663   1.779       0.629  
                                30 months        8         0         14.62     1.683   0.595  
      36 months        8          0        7.60       1.09        0.385  
 
Source of Variation      DF             SS       MS        F           P   
              Between Groups        2         232.082      116.041   48.433 <0.001  
              Residual                    21         50.314    2.396    
              Total                                23         282.396       
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
:  
Comparison                       Diff of Means p q P P<0.050  
       30 months vs. 36 months              7.025        3    12.837  <0.001 Yes  
       30 months vs. 6 months              0.963        3    1.759      0.442 No  
       6 months vs. 36 months                6.063        3    11.078  <0.001 Yes 
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p-GSK-3ß EDL  
Film properties report p-GSK-3ß EDL  
Experimenter: Sreevani Uddemarri      Muscle :  EDL  Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 10% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p- GSK-3ß(Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 5 sec    Molecular weight: 45 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl 
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
p- GSK-3ß in EDL Data set 
Raw %IOD values 
Raw IOD values (relative percentage) 
 
6 
Control 
6 
5 min 
6 
15 min 
30  
Control 
30  
5 min 
30  
15 min 
36 
Control 
36 
5 min 
36  
15 min 
Raw values 14.3 13.6 14.8 11.2 10.3 12.4 8.8 7 7.5 
 14.5 12.3 14.5 11.2 10.6 12.4 9.3 7.5 7.8 
 15.2 12.8 14.6 11.9 10 11.9 8.7 7.2 7.8 
 13.8 12 14.2 11.6 10.8 12.6 9.3 7 8.7 
 13.9 12.1 14.4 10.6 10.7 11.8 10.6 7.4 8.3 
 13.1 14.5 16 13.4 10.9 11.5 7.7 6.3 6.6 
 13.6 14.5 15.8 12.7 10.8 11.2 7.9 6.7 6.9 
 13.3 13.9 16.1 13.1 9.8 11.7 8.3 7.1 6.8 
 14.3 13.6 14.8 11.2 10.3 12.4 8.8 7 7.5 
N 8 8 8 8 8 8 8 8 8 
Mean 13.9625 13.2125 15.05 11.9625 10.4875 11.9375 8.825 7.025 7.55 
Strandard Deviation 0.684392 1.045313 0.781939 1.004188 0.408613 0.489716 0.926977 0.384522 0.74642 
Standard Error of the mean 0.258676 0.395091 0.295545 0.379547 0.154441 0.185095 0.350364 0.145336 0.28212 
Relative Expression Level 100 94.6285 107.7887 85.6759 75.1119 85.4969 63.205 50.3133 54.0734 
Standard error of the mean 1.8526 2.8297 2.1167 2.7183 1.1061 1.3257 2.5093 1.0409 2.0206 
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Statistics 
One Way Analysis of Variance  
                                          Normality Test: Passed (P > 0.200) 
                                        Equal Variance Test: Passed (P = 0.037) 
                            Group Name       N    Missing Mean   Std Dev    SEM  
                            6 5                     8        0            13.213    1.045      0.370  
                            6 15                     8        0            15.050    0.782      0.276  
                            30 control         8        0            11.963   1.004       0.355  
                            30 5                     8        0            10.488   0.409       0.144  
                            30 15         8        0            11.938   0.490       0.173  
                            36 control         8        0            8.825   0.927       0.328  
                            36 5                     8        0            7.025   0.385       0.136  
                            36 15         8        0            7.550   0.746       0.264  
                   
Source of Variation    DF       SS          MS        F          P 
Between Groups    7 442.592    63.227 107.999   <0.001 
                  Residual                      56     32.785      0.585 
                  Total                      63     475.377 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
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GSK-3ß Soleus 
Film properties report GSK-3ß Soleus  
Experimenter: Sreevani Uddemarri   
Muscle :  Soleus   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 10% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: GSK-3ß(Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 45kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
 
GSK-3ß in Soleus Data set 
Raw IOD values (relative percentage)  
 6 months 30 months 36 months 
Raw values 42.1 30.9 26.9 
 38.7 35 26.3 
 39.1 32.9 28.1 
 42.9 28.2 28.9 
 44.8 26.4 28.8 
 38.4 32.8 28.8 
 38.4 32.9 28.7 
 39.6 33 27.4 
 43.8 28.1 28.1 
N 9 9 9 
Mean 40.86667 31.13333 28 
Strandard Deviation 2.532785 2.909467 0.939415 
Standard Error of the mean 0.895475 1.028652 0.332133 
% Relative expression 100 76.1827 68.5155 
SE 2.1912 2.5171 0.8127 
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Statistics 
One Way Analysis of Variance  
 
Normality Test: Passed (P > 0.200) 
Equal Variance Test: Passed (P = 0.193) 
 
                Group Name      N      Missing           Mean      Std Dev   SEM  
                6 month              9           0                  40.867     2.533   0.844  
          30 month  9   0           31.133     2.909   0.970  
                             36 month         9          0                  28.000     0.939    0.313  
 
                          Source of Variation        DF     SS        MS    F    P   
                              Between Groups         2          810.320    405.160 77.112   <0.001
      Residual                    24         126.100   5.254    
                               Total                     26          936.420     
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
 
            Comparison                    Diff of Means       p     q    P    P<0.050  
             6 months vs. 36 months 12.867                    3 16.840   <0.001 Yes  
             6 months vs. 30 months 9.733                    3 12.739   <0.001 Yes  
             30 months vs. 36 months 3.133                    3 4.101     0.021 Yes  
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p- GSK-3ß Soleus 
Film properties report p- GSK-3ß Soleus 
Experimenter: Sreevani Uddemarri   
Muscle :  Soleus   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 10% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p- GSK-3ß(Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 15 sec    Molecular weight: 45 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
p- GSK-3ß in Soleus Data set 
Raw IOD values (relative percentage) 
 
6 
Control 
6 
5 min 
6 
15 min 
30  
Control 
30  
5 min 
30  
15 min 
36 
Control 
36 
5 min 
36  
15 min 
Raw values 15.7 11.2 11.8 10.8 8.5 11.7 10.4 9.4 10.5 
 15.4 11.4 11.7 11.1 9.1 11.1 10.1 9.6 10.5 
 16.2 11.1 11.3 11.4 9.2 11.2 10.2 9.2 10.2 
 14.1 9.9 10.2 10.6 9.9 10.4 10.8 10.8 13.2 
 14.8 10.8 10.4 11 10 10.3 10.6 9.8 12.4 
 14.5 11.9 11.1 10.9 10.1 10.1 10.1 10.1 11.1 
 15.6 12.1 11.3 10.4 9.5 12.8 10.5 9.7 8.2 
 14.9 11.6 10.6 11 10.4 13.4 10.6 9.3 8.1 
 15.7 12.5 11.3 9.4 10.1 13.6 11 8.7 7.7 
N 9 9 9 9 9 9 9 9 9 
Mean 15.21111 11.38889 11.07778 10.73333 9.644444 11.62222 10.47778 9.622222 10.21111 
Strandard Deviation 0.67536 0.768838 0.560753 0.576628 0.612599 1.345156 0.311359 0.595352 1.919925 
Standard Error of the mean 0.238776 0.271825 0.198256 0.203869 0.216587 0.475584 0.110082 0.210489 0.678796 
Relative Expression Level 100 74.8722 72.8269 70.5625 63.4039 76.4061 68.8824 63.2579 67.1293 
Standard error of the mean 1.5697 1.787 1.3034 1.3403 1.4239 3.1266 0.7237 1.3838 4.4625 
 
Sreevani Uddemarri   4/25/2005 
 
115
 
Statistics 
One Way Analysis of Variance 
Normality Test: Failed (P = 0.008) 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
                     Group       N       Missing  Median     25%      75% 
                    6 control       9      0             15.400    14.725 15.700 
                    65 min       9      0             11.400   11.025 11.950 
                    615 min       9      0             11.300   10.550 11.400 
                    30 control      9      0             10.900   10.550 11.025 
                    30 5 min       9      0             9.900    9.175 10.100 
                    3015 min       9      0            11.200   10.375 12.950 
                    36 control      9      0            10.500   10.175 10.650 
                    36 5 min       9      0             9.600    9.275 9.875 
                    3615 min       9      0            10.500   8.175             11.425 
H = 50.198 with 8 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001) 
To isolate the group or groups that differ from the others use a multiple comparison 
procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparison           Diff of Ranks      q P<0.05 
                               6 control vs 30 5 min 555.000 7.863 Yes 
                               6 control vs 365 min 555.000 7.863 Yes 
                               6 control vs 3615 min 403.000 5.710 Yes 
                               6 control vs 36 control 391.500 5.547 Yes 
                               6 control vs 30 control 321.000 4.548 Yes 
                               6 control vs 6 15 min 249.000 3.528 No 
                   6 control vs 3015 min 232.500 3.294 Do Not Test 
                               6 control vs 6 5 min 209.000 2.961 Do Not Test 
                               6 5 min vs 30 5 min 346.000 4.902 Yes 
                               6 5 min vs 36 5 min 346.000 4.902 Yes 
                               6 5 min vs 3615 min 194.000 2.749 No 
                         6 5 min vs 36 control       182.500 2.586   Do Not Test 
     6 5 min vs 30 control       112.000      1.587  Do Not Test 
                               6 5 min vs 6 15 min 40.000             0.567 Do Not Test 
                               6 5 min vs 30 15 min 23.500             0.333 Do Not Test 
                               30 15 min vs 30 5 min 322.500 4.569 Yes 
                               30 15 min vs 36 5 min 322.500 4.569 Yes 
                   30 15 min vs 36 15 min    170.500 2.416 Do Not Test 
                   30 15 min vs 36 control    159.000 2.253 Do Not Test 
           30 15 min vs 30 control    88.500     1.254   Do Not Test 
                               30 15 min vs 615 min 16.500             0.234 Do Not Test 
                               6 15 min vs 30 5 min 306.000 4.336 No 
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SHP-2 EDL 
Film properties report SHP-2 EDL 
Experimenter: Sreevani Uddemarri   
Muscle :  EDL   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: SHP-2(Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 72 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
SHP-2 in EDL Data set 
Raw IOD values (relative percentage) 
 6 month 30 month 36 month 
Raw values 31 36.9 32.1 
 31.2 38.1 30.7 
 31.5 37.6 30.9 
 17.3 40.4 42.3 
 17.3 40.8 41.8 
 16.1 41.1 42.9 
 31.8 32.6 35.7 
 31.2 31.7 37.2 
 31.6 31.2 37.2 
N 9 9 9 
Mean 26.55556 36.71111 36.75556 
Strandard Deviation 7.253811 3.948558 4.84874 
Standard Error of the mean 2.56461 1.396026 1.714288 
% Relative expression 100 138.2427 138.41 
SE 9.657526 5.257002 6.455479 
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Statistics 
One Way Analysis of Variance  
 
Normality Test: Passed (P = 0.012) 
Equal Variance Test: Passed (P = 0.486) 
Group Name       N  Missing    Mean    Std Dev    SEM  
                                6 control         9        0       26.556   7.254 2.418  
             30 control  9 0        36.711    3.949      1.316  
             36 control  9 0        36.756  4.849     1.616  
 
Source of Variation   DF        SS   MS         F          P   
       Between Groups         2   621.532    310.766   10.165 <0.001  
       Residual                   24 733.753     30.573    
                           Total                          26  1355.285     
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference (P = <0.001). 
 
Power of performed test with alpha = 0.050: 0.967 
 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparison       Diff of Means p q P P<0.050  
              36 mon vs. 6 mon 10.200              3 5.534 0.002   Yes  
              36 mon vs. 30 mon 0.0444              3 0.0241 1.000    No  
              30 mon vs. 6 mon 10.156              3 5.510 0.002   Yes  
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p-SHP-2 EDL 
Film properties report p-SHP-2 EDL 
Experimenter: Sreevani Uddemarri   
Muscle :  EDL   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p-SHP-2(Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 72 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
 
p-SHP-2 in EDL Data set 
Raw IOD values (relative percentage) 
 
 
6 
Control 
6 
5 min 
6 
15 min 
30  
Control 
30  
5 min 
30  
15 min 
36 
Control 
36 
5 min 
36  
15 min 
Raw values 15.7 11 13.8 16.4 14.3 9.8 10.4 6.6 2.2 
 14.5 9.9 13 16.9 15.5 10.2 10.8 6.7 2.4 
 15 9.4 12.9 16.6 15.7 9.9 10.9 7 2.5 
 11.6 11.6 12.4 11.2 11.5 10.1 8.9 11.2 11.3 
 9.9 10.7 13 9.9 11.3 10.4 10.8 12.4 11.6 
 11.5 11.9 12.8 9.2 10.6 10.1 10.2 12.4 11.3 
N 6 6 6 6 6 6 6 6 6 
Mean 13.03333 10.75 12.98333 13.36667 13.15 10.08333 10.33333 9.383333 6.883333 
Strandard Deviation 2.338946 0.964883 0.457894 3.639047 2.280132 0.213698 0.752773 2.9027 4.949916 
Standard Error of the mean 1.046008 0.431509 0.204776 1.627432 1.019706 0.095568 0.33665 1.298127 2.21367 
Relative Expression Level 100 82.4808 99.6164 102.5575 100.8951 77.3657 79.2839 71.9949 52.8133 
Standard error of the mean 8.0256 3.3108 1.5712 12.4867 7.8238 00.7333 2.583 9.9601 16.9847 
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Statistics 
One Way Analysis of Variance 
 
Normality Test: Passed (P = 0.151) 
Equal Variance Test: Failed (P = <0.001) 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
 
Group       N      Missing  Median    25%      75%     
             6 control    6           0    13.050  11.500 15.000  
             6 5 min      6           0    10.850  9.900             11.600  
             6 15 min    6           0    12.950  12.800 13.000  
             30 control  6           0    13.800  9.900             16.600  
             30 15 min  6           0    10.100  9.900             10.200  
             30 5 min    6           0    12.900  11.300 15.500  
             36 control  6           0    10.600  10.200 10.800  
             36 5 min    6           0    9.100  6.700             12.400  
             36 15 min  6           0    6.900  2.400             11.300  
 
H = 21.588 with 8 degrees of freedom.  (P = 0.006) 
 
The differences in the median values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = 0.006) 
 
T 
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SHP-2 Soleus 
Film properties report SHP-2 Soleus 
Experimenter: Sreevani Uddemarri   
Muscle :  Soleus   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: SHP-2 (Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 72kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
SHP-2 in Soleus Data set 
Raw IOD values (relative percentage) 
 6 month 30 month 36 month 
Raw values 13.8 14 6.3 
 13.6 13.3 6.3 
 13.4 13.6 7.1 
 12.9 13.2 8.1 
 12.4 14.2 6.6 
 11.6 13.5 8.8 
N 6 6 6 
Mean 12.95 13.63333 7.2 
Strandard Deviation 0.833667 0.393277 1.035374 
Standard Error of the mean 0.372827 0.175879 0.463033 
% Relative expression 100 105.2767 55.5985 
SE 2.879 1.3581 3.5755 
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Statistics 
One Way Analysis of Variance 
 
Normality Test: Passed (P > 0.200) 
Equal Variance Test: Passed (P = 0.235) 
Group Name       N      Missing Mean   Std Dev SEM 
                      6 control    6       0          12.950 0.834          0.340 
                      30control    6       0          13.633 0.393          0.161 
                      36control    6       0          7.200 1.035          0.423 
 
Source of Variation DF          SS           MS          F          P 
                    Between Groups           2          149.834      74.917     116.957 <0.001 
                    Residual                       15         9.608      0.641 
                    Total                       17        159.443  
 
The differences in the mean values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001). 
 
Power of performed test with alpha = 0.050: 1.000 
 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
Comparison           Diff of Means p q P P<0.050 
                  30control vs. 36control 6.433       3  19.689  <0.001 Yes 
                  30control vs. 6control 0.683       3  2.091     0.328  No 
                  6control vs. 36control 5.750       3 17.598   <0.001 Yes 
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p-SHP-2 Soleus 
Film properties report p-SHP-2 Soleus 
Experimenter: Sreevani Uddemarri   
Muscle :  Soleus   Species: F344 X BN hybrid rat 
Protein concentration: 60 µg/ml Gel type: 7.5% Tris-HCL SDSPAGE 
Electrophoresis Voltage: 125V Transfer Voltage: 24V  Duration: 45 min   
Primary Antibody: p-SHP-2(Cell Signaling) Primary Antibody Dilution: 1:1000 
Incubation Time: overnight @ 4°C   Medium: 5% BSA  
Secondary Antibody: Anti Rabbit     Secondary Antibody Dilution: 1:1000 
Incubation Time: 1hr @ room temp  Medium: 5% milk in TBS-T 
Exposure Time 3 min    Molecular weight: 72 kDa 
Lane 1: Rainbow Marker RPN756 3µl  
Lane 2: 6 month control                                                        
Lane 3: 6 month 5 min                                                                                                     
Lane 4: 6 month 15 min                                                                   
Lane 5: 30 month control  
Lane 6: 30 month 5 min  
Lane 7: 30 month 15min 
Lane 8: 36 month control 
Lane 9: 36 month 5 min 
Lane 10: 36 month 15 min  
Lane 11: NIH 3T3 Activated Cell Extract 3µl 
Lane 12: Biotinylated Ladder 3 µl  
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Raw data 
This section represents the raw data tables Produced from spot densitometry of the 
immunoblot films.  
 
p-SHP-2 in Soleus Data set 
Raw %IOD values  
 
 
Raw IOD values (relative percentage) 
 
6 
Control 
6 
5 min 
6 
15 min 
30  
Control 
30  
5 min 
30  
15 min 
36 
Control 
36 
5 min 
36  
15 min 
Raw values 13.4 17.1 14.5 15 11.4 14.7 5 5.8 3.2 
 13.8 17.7 15.7 16.1 11 13.9 4.4 4.6 2.9 
 14.2 16.8 15.3 14.9 11.5 14.5 4.5 5.3 2.9 
 9 10.5 11.3 16.5 16.3 20 5.7 5.7 4.9 
 9.8 10.2 11.8 16.8 14.7 18.8 4.6 7 6.3 
 8.9 11.2 12.4 16.7 15.9 17.9 3.9 6.6 6.4 
N 6 6 6 6 6 6 6 6 6 
Mean 11.51667 13.91667 13.5 16 13.46667 16.63333 4.683333 5.833333 4.433333 
Strandard Deviation 2.533311 3.622936 1.89842 0.848528 2.436938 2.584312 0.611283 0.868716 1.660923 
Standard Error of the mean 1.132931 1.620226 0.848999 0.379473 1.089832 1.155739 0.273374 0.388501 0.742788 
Relative Expression Level 100 120.8394 117.2214 138.9291 116.932 144.4284 40.6657 50.6512 38.4949 
Standard error of the mean 9.8373 14.0685 7.3719 3.295 9.4631 10.0354 2.3737 3.3734 6.4497 
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Statistics 
One Way Analysis of Variance 
 
Normality Test: Passed (P > 0.200) 
Equal Variance Test: Failed (P = <0.001) 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
Group      N  Missing  Median    25%      75% 
                     6 control   6 0           11.600          9.000        13.800 
                     6 5 min   6 0           14.000         10.500        17.100 
                     6 15 min   6 0           13.450         11.800        15.300 
                     30 control 6 0           16.300         15.000            16.700 
                     30 5 min   6 0           13.100         11.400        15.900 
                     30 15 min 6 0           16.300         14.500        18.800 
                     36 control 6 0           4.550         4.400         5.000 
                     36 5 min   6 0           5.750         5.300         6.600 
                     36 15 min 6 0           4.050         2.900         6.300 
 
H = 41.601 with 8 degrees of freedom.  (P = <0.001) 
 
The differences in the median values among the treatment groups are greater than would be 
expected by chance; there is a statistically significant difference  (P = <0.001) 
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All Pairwise Multiple Comparison Procedures (Tukey Test): 
 
   Comparison             Diff of Ranks         q     P<0.05 
                                 3015 min vs 36 control     220.000 5.709    Yes 
                                 3015 min vs 3615 min      219.000 5.683    Yes 
                                 3015 min vs 365 min        185.000 4.801    Yes 
                                 3015 min vs 6control    108.000 2.803    No 
                                 3015 min vs 615 min    61.500 1.596    Do Not Test 
                                 3015 min vs 305 min    60.500 1.570    Do Not Test 
                                 3015 min vs 65 min    45.500 1.181    Do Not Test 
                                 3015 min vs 30control    0.500 0.0130    Do Not Test 
                                 30 control vs 36control   219.500 5.696      Yes 
                                 30 control vs 3615 min    218.500 5.670      Yes 
                                 30 control vs 365 min   184.500 4.788        Yes 
                                 30 control vs 6control     107.500 2.790       Do Not Test 
                                 30 control vs 615 min  61.000 1.583       Do Not Test 
                                 30control vs 30 5 min  60.000 1.557     Do Not Test 
                                 30control vs 6 5 min  45.000 1.168     Do Not Test 
                                 65 min vs 36 control 174.500 4.528     Yes 
                                 65 min vs 3615 min 173.500 4.502     Yes 
                                 65 min vs 365 min 139.500 3.620      No 
                                 65 min vs 6control 62.500             1.622      Do Not Test 
                                 65 min vs 615 min 16.000             0.415      Do Not Test 
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BUFFERS AND PROTOCOLS 
 
Krebs-Ringers Solution 
 
Chemicals 
 All chemicals listed below were purchased from Sigma Chemical Company 
  NaCl    KCl 
  MgSO4   NaH2PO4 
  CaCl2    NaHCO3 
  α-D-Glucose   d-tubocurarine chloride 
Preparation of Concentrated (10x) Krebs-Ringers stock solution 
 10x Salt Stock (in 1000ml deionized water) 
  68.96 g NaCl   3.5 g KCl 
  14 g MgSO4   1.5 g NaH2PO4 
 10x Calcium Stock (in 1000ml deionized water) 
  2.78 g CaCl2 
 10x Bicarbonate Stock (in 1000ml deionized water) 
  21.0 g NaHCO3 
*Stock solutions stored in refrigerator 
Final Concentrations of Krebs-Ringers Working Solution   
  118 mM NaCl   4.7 mM KCl 
  1.2 mM MgSO4  1.2 mM NaH2PO4 
  2.5 mM CaCl2   25mM NaHCO3 
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  10 mM α-D-Glucose 
Preparation of Krebs-Ringers working solution 
 Working solution is prepared daily and discarded at the end of the experiment. A working 
KRS is prepared by adding 100 ml of 10 salt stock + 200 ml deionized water. Then, add 100 ml 
of 10x calcium stock + 200 ml deionized water. Finally, add 100 ml of 10 x bicarbonate stock. 
Add 1.8 grams of α-D-Glucose (optional add 0.017 grams d-tubocurarine chloride) and fill with 
deionized water to ≤1000 ml total volume. 
 * Oxygenate Ringer’s solution for 10 minutes with 5% Co2 and 95% O2 
 * Adjust pH to 7.4 using 1N HCl or 1N NaOH. 
 * Fill to 1000 ml total volume. 
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 T-PER lysis buffer for tissue pulverization 
 
Makes 5 ml TPER lysis buffer. 
1. 0.5 M EDTA                          10 µl 
2. 0.1 M EGTA (MW 468.4):   50 µl 
3. 1.0 M MgCL2:    7.5 µl 
3. 0.1 M NaVO3:               50 µl 
5. 0.5 M PMSF:      1 µl 
6. Protease Inhibitor Cocktail:             1 µl 
Procedure: 
1. Pre weight sample vial 
2. Pulverized sample using liquid nitrogen  
1. Place large mortis on ice,  
2. Place small mortis inside large mortis 
3. Fill small mortis with liquid nitrogen 
4. Place frozen sample in liquid nitrogen filled small mortis 
5. Dip porcelain pestle in liquid nitrogen ( to prevent sample from melting and freezing 
to pestle.  
6. Immediately grind sample with porcelain pestle Do not allow sample to warm  
7. Repeat steps c, and e-f frequently until sample has formed a powder.  
8. Take precaution to minimize exposure of skin to liquid nitrogen.  
3. Transfer pulverized sample to pre-weighed sample vial 
4. Weigh sample with sample vial 
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5. Add 1000µl lysis buffer per 1 g of pulverized sample and vortex 
6. Incubate on ice for 30 minutes, vortex every 5 minutes. 
7. Centrifuge at 14,000rpm at 4°C for 5 minutes 
8. Transfer supernatant to fresh tubes and store at -80°C 
9. Perform Bradford’s protein assay (Sample may be concentrated using a speed-vac if 
required ) 
10. Dilute with appropriate amount of water to obtain 25 or 50µl of 5µg/µl solution. (Storage 
-80°C) 
11. Add equal volume of Laemelli’s Sample buffer and store at -20°C. 
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Xylazine – Ketamine anesthesia 
  
Recipe #1 
1. In a sterile 10 ml bottle with a rubber stopper, mix 8.75 ml of Ketamine (100 mg/ml), and 
1.25 ml of Xylazine (100 mg/ml). Shake well before use. 
2. Identify the bottle, writing: “Xylazine – Ketamine for rat: 0.05 – 0.10 ml/100 g IP”, and 
the date the mix was prepared and your initials. 
3. Write the expiration date on the bottle, selecting the earliest expiration date between 
ketamine, xylazine, or water, for a maximum of 3 months. Keep away from light, in a 
cool place. 
4. Administer 0.05 – 0.10 ml/100 g IP. 
5. Repeat as required with 1/3 to 1/2 dose at a time (approximately every 30 minutes) 
6. Prevent heat loss until the animal recovers. 
 
Recipe #2 
1. In a sterile 10 ml bottle with a rubber stopper, mix 3.75 ml of Ketamine (100 mg/ml), and 
0.5 ml of Xylazine (100 mg/ml). Shake well before use. 
2. Identify the bottle, writing: “Xylazine – Ketamine for rat: 0.2 ml/100 g IP”, and the date 
the mix was prepared and your initials. 
3. Write the expiration date on the bottle, selecting the earliest expiration date between 
ketamine, xylazine, or water, for a maximum of 3 months. Keep away from light, in a 
cool place. 
4. Administer 0.2 ml/100 g IP. 
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5. Repeat as required with 1/3 to 1/2 dose at a time (approximately every 30 minutes) 
6. Prevent heat loss until the animal recovers. 
 
References   
[Flecknell, 1996 #161][DF, 1997 #162] 
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 5% Milk in TBS-T 
 
  Milk (powdered Kroger nonfat dry milk)  12.5 g 
  TBS-T       250 ml 
3% Milk in TBS-T 
 
  Milk (powdered Kroger nonfat dry milk)   7.5 g 
  TBS-T       250 ml 
 
Transfer Buffer 
 
Tris Base      3.03 g 
Glycine      14.4 g 
 Bring to 800 ml with diH2O 
 Bring to 1000ml with pure methanol(100%).  
 
 
5% BSA in TBS-T 
 
  BSA       12.5 g 
  TBS-T       250 ml 
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Bradford’s protein assay 
The Branford assay is the standard means of measuring the concentration of protein within a 
volume of supernatant.  
 
1. Label curvet for each BSA protein standard 0.25, 0.5, 1 ,1.5 and 2 
2. Label three curvets for each sample to be assayed.  
3. Load 20 µl of each BSA protein standard into the appropriately labeled curvet. 
4. Load 16 µl of water into each pre-labeled sample curvet. 
5. Load 4 µl of each sample of unknown protein concentration into the appropriately 
labeled curvet containing the previously loaded 16 µl of water. 
6. Load 1000 µl of Comassie stain into all curvets and vortex 
7. Using the mass spectrometer with the wavelength set at 595 nm, select the standard 
curve setting. 
8. Load BSA standard loaded curvets into the spectrometer, enter standards 
concentration, and run unit to set standard curve (record the r2 value). 
9. Remove all curvets with standards accept the blank in the first cell.  
10. Place curvets with unknowns and select test unknown on spectrometer. 
11. Run appropriate program and record data for each sample. 
12. Load data into excel spread sheet and multiple the concentration by 5 to determine 
unknown concentrations 
13. If concentration are too low, Speed vac to increase concentration of protein in sample, 
and repeat assay. 
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14. Calculate the appropriate volume of diH2O needed to covert all sample to the same 
protein concentrations.  
15. Dilute with appropriate amount of water to obtain 25 or 50µl of 6µg/µl solution. 
(Storage -80°C) 
16. Add equal volume of Laemelli’s Sample buffer and store at -80°C  
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